PROTOCOL:  SHP643 -102
TITLE: A Randomized, Open -label, Single -dose, Parallel -arm, Single -center, 
Phase 1 Study  to Determine the Bioavailability  of Lanadelumab 
Administered Subcutaneously  with the Prefilled Syringe and the 
Autoinjector in Health y Adult Volunteer Subjects
DRUG: SHP643, lanadelumab (formerl y DX -2930)
IND: [ADDRESS_964197] NO.: Non-EUDRACT
SPONSOR: Dyax Corp. (a wholly -owned, indirect subsidiary of Shire plc)
[ADDRESS_964198] , Lexington, MA [ZIP_CODE] [LOCATION_003]
PRINCIPAL/
COORDINATING
INVESTIGATOR:
[INVESTIGATOR_59649]:Original Protocol:  [ADDRESS_964199] fax or e -mail the "Shire Clinical Study  Adverse 
Event Form for Serious Adverse Events (SAEs) and Non- serious AEs as Required b y the 
Protocol" within 24 hours to the Shire Global Drug Safety  Department. The fax number and e -
mail address ar e provided on the form (sent under separate cover). A copy  of this form must also 
be sent to the contract research organization (CRO) (as app licable)/Shire Medical Monitor using 
the details below.
E
-mail: 
For protocol -or safety- relate d questions or concerns during normal business hours the 
investigator must contact [CONTACT_317344]:
 (Business hours)
 (24-hour coverage)
Forprotocol -or safety- related questions or concerns outside of normal business hours , the 
investigator must contact [CONTACT_317344]:
 (24-hour coverage)
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_964200](s) will be returned to the 
sponsor for inspection and anal ysis according to procedures.
This includes any  instances wherein the quality  or performance of a Shire product (marketed or 
investigational) does not meet expectations (eg, inadequate or fault y closure, product 
contamination); or that the product did not meet t he specifications defined in the application for 
the product (eg, wrong product such that the label and contents are different products); or a 
product deficiency  that relates to identity , qualit y, durability , reliability , safety  and performance 
of the product but did not result in an AE, which include but are not limited to the following:
A failure of a product to exhibit its expected pharmacological activit y and/or design 
function, eg, reconstitution difficulty
Missing components
Damage to the product or unit carton
A mislabeled product (eg, potential counterfeiting/tampering)
A bacteriological, chemical, or ph ysical change or deterioration of the product causing it 
to malfunction or to present a hazard or fail to meet label claims
For instructions on repor
ting AEs related to product complaints, see Appendix [ADDRESS_964201] Quality Complaint or Non -
Medical Complaint:
Origin of Product Quality Complaint E-mail Address
North and South America
European Union and Rest of World
Telephone number (provided for reference if needed):
Shire, Lexington, MA ([LOCATION_003])
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_964202] OF FIGURES .........................................................................................................................9
ABBREVIAT IONS .......................................................................................................................10
STUDY SYNOPSI S
......................................................................................................................12
STUDY SCHEDULE(S) ...............................................................................................................[ADDRESS_964203] Background .................................................................................................21
1.2.1 Preclinical Information ..........................................................................................21
1.2.2 Clinical I nformation ...............................................................................................21
1.3 Risk/Benefit and Ethical Assessment .......................................................................21
1.4 Compliance Statement ..............................................................................................21
2.STUDY OBJECTIVES AND PURPOSE ..............................................................................22
2.1 Rationale for the Study .............................................................................................22
2.2 Study  Objectives ......................................................................................................22
2.2.1 Primary  Objective ..................................................................................................22
2.2.2 Secondary  Objective ..............................................................................................22
2.2.3 Exploratory  Objectives ..........................................................................................22
3.STUDY DESIGN ...................................................................................................................23
3.1 Study  Design and Flow Chart ..................................................................................23
3.2 Duration and Study  Completion Definition .............................................................24
3.3 Sites and Regions .....................................................................................................24
4.STUDY POPUL ATION.........................................................................................................25
4.1 Inclusion Criteria
................................ ................................ ................................ ......25
4.2 Exclusion Criteria ................................ ................................ ................................ .....25
4.3 Restrictions ...............................................................................................................27
4.4 Reproductive Potential ................................ ................................ ............................. 27
4.4.1 Female Contraception ................................ ................................ ............................ 27
4.4.2 Male Contraception ................................ ................................ ................................ 28
4.5 Discontinuation of Subjects ................................ ................................ ..................... 28
4.5.1 Reasons for Study  Discontinuation ................................ ................................ ........ 29
4.5.2 Subjects ‘L ost to Follow -up’ Prior to Last Scheduled Visit ..................................[ADDRESS_964204] Compliance ..................................................................................................34
6.6 Retention of Bioavailability  and Bioequivalence Testing Samples .........................34
7.
STUDY PROCEDURES........................................................................................................35
7.1 Study  Schedule .........................................................................................................35
7.1.1 Screening Period ....................................................................................................35
[IP_ADDRESS] Screening Failure ....................................................................................35
[IP_ADDRESS] Rescreening of Subjects .........................................................................35
7.1.2 Treatment Period ....................................................................................................36
[IP_ADDRESS] In-house Confinement Period (Day  1 to Day  5)....................................36
[IP_ADDRESS] Out-Patient Visit Period (Day  7-112)................................ ..................... 36
[IP_ADDRESS] Final Visit (Day  112)................................ ................................ .............. 36
7.1.3 Additional Care of Subjects After the Study ................................ ......................... 36
7.2 Study  Evaluations and Procedures ................................ ................................ ........... 36
7.2.1 Demographic and Other Baseline Characteristics .................................................36
7.2.2 Safety ................................ ................................ ................................ ..................... 36
[IP_ADDRESS] Medical and Medication History ................................ ............................ 37
[IP_ADDRESS] Physical Examination (Including Height and Weight) ..........................37
[IP_ADDRESS]
Adverse Event Collection................................ ................................ .......38
[IP_ADDRESS] Vital Signs ................................ ................................ .............................. 38
[IP_ADDRESS] Clinical L aboratory  Tests ................................ ................................ .......39
[IP_ADDRESS] Pregnancy  Test ................................ ................................ ....................... 41
For non-commercial use only
Shire CONFIDENTIAL Page 7
SHP643 -102 Protocol
Lanadelum ab 29 Jan 2019
[IP_ADDRESS] Drug and Alcohol Screen .......................................................................41
[IP_ADDRESS] Serology  Screen ......................................................................................42
[IP_ADDRESS] Electrocardiogram ..................................................................................42
7.2.3 Pharmacokinetic Procedures ..................................................................................43
[IP_ADDRESS] Blood Sample Collection and Handling Procedures ..............................43
[IP_ADDRESS] Shipment of Plasma, Pharmacokinetic Samples ....................................43
[IP_ADDRESS] Plasma Drug Assay  Methodology ..........................................................44
[IP_ADDRESS] Immunogenicit y Testing for Anti -Drug Antibodies ...............................[ADDRESS_964205] ................................................44
8.DATA MANAGEMENT AND STATISTICAL METHODS
...............................................46
8.1 Data Collection .........................................................................................................46
8.2 Clinical Data Management .......................................................................................46
8.3
Data Handling ..........................................................................................................46
8.4 Statistical Analy
sis Process ......................................................................................46
8.5 Planned Interim Anal ysis, Adaptive Design, and Data Monitoring Committee ......47
8.6
Sample Size Calculation and Power Considerations................................................47
8.7 Study  Population ......................................................................................................47
8.8 Analy sis of Disposition ............................................................................................47
8.9 Demographics and Baseline Characteristics Anal yses.............................................48
8.10 Treatment Compliance and Extent of Exposure ......................................................48
8.11 Pharmacokinetic Anal yses.......................................................................................48
8.11.1 Pharmacokinetic Analy sis......................................................................................48
[IP_ADDRESS] Statistical Analy sis of Pharmacokinetic Parameters ..............................48
8.12 Safety  Anal yses........................................................................................................49
8.13 Other Anal yses.........................................................................................................50
9.REFERENCES .......................................................................................................................51
10.APPENDI CES ........................................................................................................................52
Appendix 1
Protocol History ................................ ................................ ..................... 53
Appendix 2 ................... 54
Appendix 3 Regulatory , Ethical, and Study  Oversight  Considerations ....................55
Appendix 3.1 Regulatory  and Ethical 
Considerations ..................................................56
Appendix 3.2 Sponsor’s Responsibilities
................................ ................................ .....57
Appendix 3.3 Investigator’s Responsibilities ................................ ............................... 59
Appendix 3.4 Ethical Considerations ................................ ................................ ............ 62
Appendix 4 Adverse Events: Definitions and Procedures for  Recording, 
Evaluating, Follow -Up, and Reporting ..................................................[ADDRESS_964206]  OF TABLES
Table 1: Schedule of Assessments ...............................................................................17
Table 2: Detailed Schedule of In -Patient Assessments (Day s 1-5).............................18
Table 3: Detailed Schedule of Out -Patient Assessments (Study  Day s 7
-112) ............19
Table 4: Volume of Blood to Be Drawn from Each Subject .......................................[ADDRESS_964207]  OF FIGURES
Figure 1: Study  Design Flow Chart ..............................................................................24
Figure 2: Procedures for Screening Vital Signs (Blood Pressure -
Pulse) -
Health y Subjects Only ...................................................................................39
For non-commercial use only
Shire CONFIDENTIAL Page 10
SHP643 -102 Protocol
Lanadelum ab 29 Jan 2019
ABBREVIA TIONS
ADA anti-drug antibod y
AE
AI
aPTT
BA
BEadverse event
autoinjector
activated partial thromboplastin time
bioavailability
bioequivalence
-hCG
BMI
BPbeta-human chorionic gonadotropin
body  mass index
blood pressure
CM concomitant medication
CRA clinical research associate
CRC clinical research center
CRF case report form
CRO contract research organization
DMC data monitoring committee
EC ethics committee
ECG electrocardiogram
EU European Union
FDA Food and Drug Administration
FSH follicle stimulating hormone
GCP
HAEGood Clinical Practice
hereditary  angioedema
HBsAg hepatitis B surface antigen
HCV hepatitis C virus
HEOR Health Economics and Outcome Research
HIPAA Health Insurance Portability  and Accountability  Act
HIV human i mmunodeficiency virus
ICH International Conference on Harmonisation
INR international normalized ratio
IP investigational product
IRB Institutional Review Board
IRT
PE
PFS
PKinteractive response technology
physical exam
prefilled s yringe
pharmacokinetic
For non-commercial use only
Shire CONFIDENTIAL Page 11
SHP643 -102 Protocol
Lanadelum ab 29 Jan 2019
PT prothrombin time
SAE serious adverse event
SAP
SC
TEAEstatistical analy sis plan
subcutaneous
treatment emergent adverse event(s)
T3
T4triiodothy ronine
thyroxine
TSH thyroid stimulating hormone
US [LOCATION_002]
UDS urine drug screen
VS vital signs
For non-commercial use only
For non-commercial use only
Shire CONFIDENTIAL Page 13
SHP643 -102 Protocol
Lanadelum ab 29 Jan 2019
in the abdomen in a single 2 mL dose using either the PFS or the AI per their randomized assignment. This 
study is open -label and does not require the use of a placebo.
 Com parator products in this study are the PFS versus the AI.
Methodology:
This study is a Phase 1, randomized, open -label, single -dose, para llel-arm, single- center study to evaluate the 
PK, safety and tolerability of 300 mg o f lanadelumab administered to healthy adult volunteer subjects either via 
a PFS or via an AI. A total of approximately 176 subjects betw een the ages of 18 -55, inclusive, w ill be enrolled.
All randomized subjects w ill receive a single subcutaneous (SC) 300 mg dose of lanadelumab administered into 
the abdomen.  Fifty -percent of the subjects w ill receive the lanadelumab injection via a PFS, and the other 50% 
will receive the l anadelumab injection via an AI.  
The study duration will be comprised of a 28 -day screening period, one 5 -day in -house treatment period, and 
multiple out -patient visits (Day 7 [± 1 day], Day 14 [± 1 day], Day 21 [± 1 day], Day 28 [± 2 days], Day 42 
[±2days], Day 56 [± 2 days], Day 84 [± 3 days] and Day 112 [± 3 days]) after the single dose of investigational 
product is administered. The maximal total duration of study participation for a subject is approximately [ADDRESS_964208] dose.  Subjects will be admitted to the clinical research center 
(CRC) on Day -1. Day -[ADDRESS_964209] eli gibility will be determined prior 
to randomization.
In-House Confinement Treatment Period
On Day 1, all randomized subjects will receive lanadelumab as a single 2 mL 300 mg SC injection into 
the abdomen with either the PFS or the AI per their randomized assignment.
All subjects will remain in the CRC until collection of the [ADDRESS_964210] -dose PK sample on Day 5.
Assessments
Serial blood samples for PK analysis will be collected for the determination of plasma lanadelumab 
concentrations from Day [ADDRESS_964211] dose during the in -house confinement 
period and up to Day 112 during the out -patient visit period. These blood samples will be collected 
according to the Schedule of Assessments .
Safety and tolerability, including immunogenicity, wi ll be determined through assessment of treatment -
emergent adverse events (TEAEs), vital signs, electrocardiogram (ECG), antidrug antibodies (ADAs) 
and clinical laboratory evaluations on Day [ADDRESS_964212] dose during the in -house 
confine ment period and up to Day 112 during the out -patient visit period according to the Schedule of 
Assessments.
Out-Patient Visit Period
Out-patient visits will be completed on the following study days:
Day 7 (± 1 day; ie, Day 6, 7, or 8) 
Day 14 (± 1 day; ie, Day 13, 14 or 15) 
Day 21 (± 1 day; ie, Day 20, 21 or 22) 
Day 28 (± 2 days; ie, Day 27, 28 or 29) 
Day 42 (± 2 days; ie, Day 40, 41, 42, 43 or 44) 
Day 56 (± 2 days; ie, Day 54, 55, 56, 57 or 58) 
Day 84 (± 3 days; ie, Day 81, 82, 83, 84, 85, 86 or 87) 
Day 112 (± 3 days; ie, Day 109, 110, 111, 112, 113, 114 or 115) 
after the single dose of investigational product is administered. 
For non-commercial use only
Shire CONFIDENTIAL Page 14
SHP643 -102 Protocol
Lanadelum ab 29 Jan 2019
Inclusion and exclusion criteria:
Inclusion Criteria:
1.An understanding, ability, and w illingness to fully comply with study procedures and restrictions.
2.Ability to voluntarily provide written, signed, and dated informed consent to participate in the study.
3.Age [ADDRESS_964213] be considered “healthy ”,perthe investigator .Healthy status is defined by [CONTACT_363581] a detailed medical and surgical history, a complete physical examination 
including vital signs, 12 -lead ECG, hematology, blood chemistry, and urinalysis.
6.Body  mass index between 18.5 -33 kg/m², inclusive, with a body weight ≥45 kg (99 lbs). This inclusion 
criterion w ill only be assessed at the initial screening visit and on Day -1. 
7.Willing and able to consume standardized meals during the confinement period of the study. All 
participants will be required to consume the identical meals on study days when serial PK blood samples 
are collected.
Exclusion Criteria:
1.Per the investig ator, a history of any hematological, hepatic, respi[INVESTIGATOR_696], cardiovascular, renal, 
neurological or psychiatric disease, gall bladder removal, or current or recurrent disease that could 
affect the action, absorption, or disposition of the investigational pr oduct, or clinical or laboratory 
assessments.
2.Per the investigator, a current or relevant history of physical or psychiatric illness, any medical disorder 
that may require treatment or make the subject unlikely to complete the study, or any condition that 
presents undue risk from the investigational product or procedures.
3.Known or suspected intolerance or hypersensitivity to the investigational product, closely -related 
compounds, or any of the stated ingredients.
4.Significant illness, as judged by [CONTACT_3170], within [ADDRESS_964214] year, per the investigator.
6.Donation of blood or blood products (eg, plasma or platelets) w ithin [ADDRESS_964215]:
a.Have used an investigational product (if elimination half -life is <6 days, otherwise 5 half -
lives).
b.Have been enrolled in a clinical study (including vaccine stu dies) that, in the investigator’s 
opi[INVESTIGATOR_1649], may impact this Shire -sponsored study.
8.Confirmed systolic blood pressure (BP) >139 mmHg or <89 mmHg, and diastolic BP >89 mmHg or 
<49mmHg.
9.Twelve-lead ECG values demonstrating QTcF >450 msec (males) or >470 msec (females) at the 
screening visit or Day -1. If QTcF exceeds 450 msec (males) or 470 msec (females), the ECG should 
be repeated [ADDRESS_964216]’s eligibility.
10.Positive screen for drugs of abuse and/or disallow ed drugs (ie, amphetamines, benzodiazepi[INVESTIGATOR_1651], 
barbiturates, cocaine, opi[INVESTIGATOR_858], phencyclidine) at screening, or drugs of abuse or alcohol on Day -1. This 
screen will include marijuana.
For non-commercial use only
Shire CONFIDENTIAL Page 15
SHP643 -102 Protocol
Lanadelum ab 29 Jan 2019
11.Male subjects who consume more than 21 unit s of alcohol per w eek or 3 units per day. Female subjects 
who consume more than 14 units of alcohol per w eek or 2 units per day. One alcohol unit=1 beer or 1 
wine (5 oz/150 mL) or 1 liquor (1.5 oz/40 mL) or 0.75 oz alcohol.
12.Positive HIV, HBsAg, or HCV anti body  screen.
13.Use of tobacco in any form (eg, smoking or chewing) or other nicotine -containing products in any form 
(eg, gum, patch, electronic). Ex -users must report that they have stopped using tobacco for at least [ADDRESS_964217].
14.Routine consumption of more than 2 units of caffeine per day or subjects who experience caffeine 
withdrawal headaches. One caffeine unit is contained in the follow ing items: one 6 oz (180 mL) cup of 
coffee, two 12 oz (360 mL) cans of cola, one 12 oz cup of tea, and three 1 oz (85 g) chocolate bars. 
Decaffeinated coffee, tea, or cola are not considered to contain caffeine.
15.Current use of any medication (including over -the-counter, herbal, or homeopathic preparations; with 
the excepti on of stable hormonal replacement therapy or hormonal contraceptives). Current use is 
defined as use within [ADDRESS_964218]. (Prior and Concomitant 
Treatment) for a list of permitted medications.
16.Abnorm al laboratory values co nsidered clinically significant, as determined by [CONTACT_093], at 
screening or Day -1.
17.History of any clinically significant surgery or procedure w ithin [ADDRESS_964219] involvem ent in the study:
Planned duration of screening period: 28 days maximum
Planned duration of in -house confinement period: 5 days 
Planned duration of out -patient visit period: 107 days
Endpoints and statistical analysis:
Pharm acokinetic parameters:
AUC 0-last: Area under the concentration -time curve from time zero to the last quantifiable 
concentration in plasma
AUC 0
-∞: Area under the concentration -time curve from time zero extrapolated to infinity based 
on the predicted concentration at t last
Cmax: Maximum observed plasma drug concentration
tmax: Minimum time to reach C max
t½: Terminal half -life
CL/F: Apparent total body clearance for extravascular administration divided by [CONTACT_709204]
Vdz/F: Apparent vo lume of distribution associated with the terminal slope following extravascular 
administration divided by [CONTACT_323934]
z: First order rate constant associated w ith the terminal (log -linear) portion of the curve
Safety endpoints:
Treatment- emergent adverse events (TEAEs)
Clinical laboratory results (hematology, clinical chemistry, coagulation and urinalysis)
Vital signs (including BP, pulse, body temperature), and 12 -lead ECG
Antidrug antibodies (ADA) 
Analysis sets:
Safety a nalysis set, defined as all randomized subjects who received the dose of lanadelumab 
For non-commercial use only
Shire CONFIDENTIAL Page 16
SHP643 -102 Protocol
Lanadelum ab 29 Jan 2019
(study drug). All safety analyses will be based on the safety analysis set.
Pharmacokinetic analysis set, defined as all randomized subjects who received the dose of 
lanad elumab and have at least [ADDRESS_964220] -dose PK concentration value. All PK analyses will 
be based on the PK analysis set.
For non-commercial use only
Shire CONFIDENTIAL Page 17
SHP643 -102 Protocol
Lanadelum ab 29 Jan 2019
STUDY  SCHEDULE(S)
Table 1: Schedule of Assessments
Visit ScreeningIn-House 
Treatment 
Period aOut-Patient
Visitsb, 
cEnd of Study
(Day 112) or
Early 
Discontinuation  
Study Day–28 to    -
02-1h1 to 5   7 to 112
Informed consent X
Refer to Table 2
Refer to Table 3Inclusion/exclusion criteria X X
Demography X X 
Medical/Medication History X X X
Physical examination X X X
Vital signs (blood pressure, pulse) supi[INVESTIGATOR_050] X X X
Body temperature (oral) X X X
Height, Weight and BMId,eX X X
Electrocardiogram (12 -lead) XfXfX
Biochemistry, hematology, and urinalysis X X X
TSH, T3, T4 X
PT, aPTT, INR X X X
HIV, HBsAg, and HCV antibodies X
Serum Pregnancy test (all females) X X X
FSH (all females) X
Urine drug and alcohol (breath test) 
screeningX X
Pharmacokinetic blood sampling  (PK) X
Anti-drug antibody blood sampling (ADA) X X
Check -in to the CRC X
Out-patient visits X X
In-patient visit X
Concomitant Medication X X X
Adverse Event/Serious Adverse Event X X X
aPTT= activated partial thromboplastin time; CRC= clinical research center; HBsAg=hepatitis B surface antigen; HCV=hepatitis 
C virus; INR=international normalized ratio; FSH=follicle-stimulating hormone; HIV=human immunodeficiency virus; 
PT=prothrombin time; T3=triiodothyronine; T4=thyroxine; TSH= thyroid-stimulating hormone
aRefer to Table [ADDRESS_964221] visit during the screening period and on Day -1.
f  Single ECG recordings  are  required; However, ECGs will be performed in triplicate ifthe QTcF interval (calculated on line on 
site) is increased by >45 msec from the baseline 4
, or an absolute QTcF value is >500 msec for any scheduled ECG, orif 
indicated per exclusion criteria #9 or in S ection [IP_ADDRESS] , then 2 additional ECGs will be colle cted, approximately 2 -4 minutes 
apart, to confirm the original measurement. Thereafter, all subsequent ECGs will be single recordings. 
For non-commercial use only
Shire CONFIDENTIAL Page 18
SHP643 -102 Protocol
Lanadelum ab 29 Jan 2019
Table 2: Detailed Schedule of In -Patient Assessments (Days 1 - 5)
Study 
Day/Hour 
(relative to 
dosing time) PE VSBody 
Temperature
(oral)Weight ECGBiochemistry, 
hematology, 
and urinalysisPT, 
aPTT, 
INRSerum 
Pregnancy 
(all women )Randomizatione IP 
administrationd PK ADA AE/SAEbCMb
Day 1PredoseaX X XXX XcX X
Day 1:0h X X X
Day1: 1h post 
dose X X X X
Day 1: 2h post 
dose X X X
Day 1:4h post 
dose X X X X
Day 1:6h post 
dose X X X
Day 1:8h post 
dose X X X X X
Day 1:12h post 
dose X X X
Day 2:24h post 
dose X X X X X X
Day 3:48h post 
dose X X X X X
Day 4: 72h post 
dose X X X X X
Day 5:96h  post 
dose X X X X X X X X X X
ADA= anti-drug antibody blood sampling; AE= adverse event; aPTT= activated partial thromboplastin time; CM= concomitant medication; CRC= clinical research center; ECG=12 -
lead ECG; HBsAg=hepat itis B surface antigen; HCV=hepatitis C virus; INR=international normalized ratio; FSH=follicle-stimulating hormone; HIV=human immunodeficiency 
virus; IP=investigational product; PE= physical exam; PT=prothrombin time; PK=pharmacokinetic blood sampling; SAE= serious adverse event; T3=
triiodothyronine;T4=thyroxine ; TSH= thyroid-stimulating hormone; UDS= urine drug screen; VS= vital signs
aAssessments to be done within 30 minutes prior the administration of IP.
bAdverse events /SAE sand C Mswill be continuo usly monitored throughout the study.
cPre-dose ADA can be collected within [ADDRESS_964222] be recorded in source and on the CRF.  
eRandomization to be performed pre-dose on Day 1.
For non-commercial use only
Shire CONFIDENTIAL Page 19
SHP643 -102 Protocol
Lanadelum ab 29 Jan 2019
Table 3: Detailed Schedule of Out -Patient Assessments (Study Days 7 - 112)
Study Day PE VSBody
Temperature
(oral)Weight ECGBiochemistry, 
hematology, 
and urinalysisPT, 
aPTT, 
INRSerum 
Pregnancy 
(all women)UDS & 
ETOH 
screenPK ADA AE/SAEaCMa
Day 7 (± 1)XX X X X X X X X X X X
Day 14 (± 1) X X X X X X X X X X X X X
Day 21 (± 1) XX X X X X X X X X X X
Day 28 (± 2) X X X X X X X X X X X X X
Day 42 (± 2) X X X X X X X X X X X X
Day 56 (± 2) X X X X X X X X X X X X X
Day 84 (± 3) X X X X X X X X X X X X
Day 112 (± 3)
(End of Study 
Visit/ or Early 
Discontinuation)X X X X X X X X X X X X X
ADA= anti-drug antibody blood sampling; AE= adverse event; aPTT= activated partial thromboplastin time; CM= concomitant medication; CRC= clinical research center; ECG=12 -
lead ECG; HBsAg=hepatitis B surface antigen; HCV=hepatitis C virus; INR=international normalized ratio; FSH=follicle -stimulating hormone; HIV=human immunodeficiency 
virus; IP= investigational product; PE= physical exam; PT=prothrombin time; PK= pharmac okinetic blood sampling; SAE= serious adverse event; T3=triiodothyronine;
T4=thyroxine; TSH= thyroid-stimulating hormone; UDS= urine drug screen; VS= vital signs
aAdverse events /SAE sand C Mswill be continuously monitored throughout the study. 
For non-commercial use only
Shire CONFIDENTIAL Page 20
SHP643 -102 Protocol
Lanadelum ab 29 Jan 2019
1. BACKGROUND INFORMATI ON
Lanadelumab (SHP643, formerl y DX -2930) is a recombinant, fully  human immunoglobulin G 
subclass 1 (IgG1), a kappa light chain monoclonal antibody  expressed in Chinese Hamster Ovary  
cells that has been studied in a double- blind, pi[INVESTIGATOR_9205] 3 study  (Study  DX-2930- 03) and is 
being studied in an on -going open
-label Phase 3 study  (Study  DX-2930- 04). L anadelumab has 
been approved by [CONTACT_3133] (FDA) for marketed use for the 
prevention of angioedema attacks in patients with hereditary  angioedema (HAE).
For further details see the current lanadelumab Investigator’s Brochure.
1.1 Indication and Current Treatment O ptions 
Lanadelumab has been developed for the prevention of angioedema attacks in patients with 
Types I or II HAE, a rare and potentially  life-threatening disease, and is indicated in the US for 
prophy laxis to prevent attacks of HAE in patients 12 y ears a nd older (reference to the FDA 
label).
Lanadelumab is a potent (Ki=125 pM) inhibitor of the proteoly tic activity  of plasma kallikrein 
(pKAL).
The activity , potency , and specificit y of lanadelumab have been demonstrated in vitro and ex 
vivo and have been co nfirmed in clinical studies.
Hereditary  angioedema is a long -term, debilitating, and potentially  life-threatening disease 
caused b y mutations in the C1 -inhibitor (C1- INH) gene, resulting in deficiency or d ysfunction of 
C1-INH protein. HAE manifests clinica lly as unpredictable, intermittent attacks of subcutaneous 
(SC) or submucosal edema of the face, lary nx, gastrointestinal tract, limbs, and/or genitalia 
(Zuraw 2008 ). Swelling may  last up to 5 day s; most patients suffer multiple attacks per y ear. 
HAE is an orphan disease. I ts exact prevalence is unknown; however, current estimates range 
from [ADDRESS_964223] estimate ( By[CONTACT_281998] 2009; Goring et al. 1998; Lei et al. 2011 ; Nordenfelt et al. 
2014; [COMPANY_002] et al. 2005 ).
Currently , HAE drugs are indicated either for prophy laxis against attacks or for treatment of 
acute attacks. Acute treatments include purified, plasma -derived C1
-INH, recombinant C1 -INH, 
a plasma kallikrein inhibitor, and a brad ykinin type 2 (B2) receptor antagonist. While acute 
treatments are effective at resolving the s ymptoms of acute attacks, they  do not prevent attacks 
and thus leav e patients at risk of developi[INVESTIGATOR_363574] y life -threatening attacks. 
Agents previousl y used for proph ylaxis include purified plasma- derived C1 -INH, attenuated 
androgens, and antifibrinoly tic agents. 
These currentl y available therapi[INVESTIGATOR_709200]; 
lanadelumab has been developed as a proph ylactic therapy with improved efficacy, a longer half -
life and a more convenient administration frequency .
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_964224] Background
1.2.1 Preclinical Information
Nonclini cal studies to evaluate the pharmacokinetic (PK) and toxicology  of sy stemicall y 
administered lanadelumab have been completed in rats and cy nomolgus monkey s.
Single -dose, 28 -day and 6 -month multidose studies of sy stemically  administered lanadelumab in 
cynomolgus monkey s did not identify toxicologically  significant effects at doses up to 50 mg/kg 
administered weekly  by [CONTACT_173874]. Studies to evaluate male and female fertility  in the 
cynomolgus monkey , at similar dose levels, revealed no adverse treatment -related findings. 
There were no adverse treatment -related findings after 28 day s of IV dosing up to 50 mg/kg. 
In addition, results from a separate lanadelumab single- dose SC injection study  to evaluate 
potential toxicity  and toxicokinetic profiles in Sprag ue-Dawley  rats showed lanadelumab to be 
well-tolerated at doses up to 50 mg/kg.
Refer to the lanadelumab I nvestigator’s Brochure for further information.
1.2.2 Clinical Information
The clinical development program for lanadelumab consists of two completed Phase 1 studies: a 
single -ascending dose Phase 1a Stud y, DX2930 -01 in healthy  adult subjects and a multiple -
ascending dose and Phase 1b Study  DX2930 -02 in adult subjects with HAE; a completed pi[INVESTIGATOR_22735], 
double -blind, placebo -controlled Phase 3 Study  DX2930- 03 (HEL P Study®), a Japanese 
bridging Phase 1 stud y (SHP643 -101) in healthy  adult subjects and one ongoing open- label 
Phase 3 Study  DX2930 -04 (HEL P Study  Extension™) in adolescent and adult subjects with 
HAE.
1.3 Risk/Benefit and Ethical Assessment
There is no antici pated benefit from taking part in this study .
Alway s refer to the latest version of the lanadelumab investigator’s brochure (IB) for the overall 
benefit/risk assessment and the most accurate and current information regarding metabolism, 
pharmacokinetics, efficacy , and safet y of lanadelumab.
1.4 Compliance Statement
This study  will be conducted in accordance with this protocol, the I nternational Council for 
Harmonisation Guideline for Good Clinical Practice E6 (ICH GCP, 1996; E6 R2, 2017), Title 21 
of the US C ode of Federal Regulations (US CFR), the EU Directives (2001/20/EC; 2005/28/EC), 
and applicable national and local regulatory  requirements.
The responsibilities of the study  sponsor and investigator(s) are described fully  in Appendix [ADDRESS_964225] from the vial. 
Lanadelumab has been prepared and admin istered via vial and sy ringe throughout the clinical 
development of the drug for treatment of HAE. The FDA agreed that no dedicated PK study 
would be required for the transition from a vial to a prefilled s yringe (PFS ); (FDA 
correspondence on IND 116647 da ted 13 January 2017). A clinical bioequivalence study , 
however, is necessary  to bridge between the PFS and the autoinjector (AI), which is also 
currentl y under development at Shire. Shire considers that the AI will be more convenient for use 
by [CONTACT_102] (fewer preparation steps and easier administration) in comparison with other 
potential delivery  methods (eg, vial / sy ringe or PFS). Extensive in vitro device design 
verifications will be performed to demonstrate the accuracy  and consistency  of dose deliv ery 
using the AI device, according to full ISO11608:2014 standards.
This study  is being conducted to assess the bioavailability  (BA) of lanadelumab administered as 
a single subcutaneous (SC) dose of 300 mg delivered by  a 2mL PFS or a 2 mL AI in healthy  
adult volunteer subjects and to evaluate the safet y and tolerability  of a single SC 300 mg dose of 
lanadelumab administered via PFS or AI. This study  may  be used to support the use of an AI -
based injection s ystem in patients with HAE.
2.2 Study Objectives
2.2.1 Primar y Objective
To evaluate bioavailability of lanadelumab following a single, 2 mL subcutaneous (SC) dose of 
300 mg delivered b y prefilled sy ringe (PFS) or auto injector (AI) in health y adult subjects.
2.2.2 Secondary Objective
To assess the safet y and tolerability of a single 2 mL 300 mg SC injection of lanadelumab 
administered b y a PFS or AI in health y adult subjects.
2.2.3 Exploratory Objectives
For non-commercial use only
Shire CONFIDENTIAL Page 23
SHP643 -102 Protocol
Lanadelum ab 29 Jan 2019
3. STUDY DESIGN
3.1 Study Design and Flow Chart
This is a Phase 1, randomized, open- label, single dose, parallel -arm single- center study  to 
evaluate the PK, safet y and tolerability of lanadelumab administered via PFS or AI to healthy 
adult volunteer subjects. A total of approximately  176 subjects between the ages of 18 -55, 
inclusive, will be enrolled. All subjects will be randomized 1:1 to receive a single 2 mL SC dose 
300 mg of lanadelumab by [CONTACT_709205] 1 administered by  
[CONTACT_709206]. Fift y-percent of the randomized subjects will receive the 
lanadelumab injection via a PFS, and the other 50% will receive the lanadelumab injection via an 
AI. This study  is a parallel group design rather than a crossover design, as a crossover design 
was not feasible due to the long half -life of lanadelumab (approximatel y 17-21 day s). 
Randomization will be stratified b y bod y weigh t (2 strata: 45 to <80 kg and ≥80 kg) to balance 
the two study  arms more closely . 
The study  duration will comprise of a 28- day screening period, one 5- day in-house treatment 
period, and [ADDRESS_964226] will not be considered eligible for the study  without meeting all of the criteria below.
Subjects cannot be randomized before all inclusion criteria (including test results) are confirmed.
1.An understanding, ability, and willingness to fully comply  with study  procedures and 
restrictions.
2.Ability  to voluntarily  provide written, signed, and dated informed consent to participate in 
the study .
3.Age 18-55, inclusive, at the time of consent. The date of signature [CONTACT_709215]. This inclusion criterion will only be 
assessed at the first screening visit.
4.Male, or non-pregnant, non-lactating female who agrees to comply  with any applicable 
contraceptive requiremen ts of the protocol or females of non- childbearing potential.
5.Must be considered “healthy ”, per the investigator. Health y status is defined by [CONTACT_709207] a detailed medical and surgical history , a 
complete physical examination including vital signs, 12-lead ECG, hematology , blood 
chemistry , and urinal ysis.
6.Body mass index between 18.5
-33 kg/m², inclusive, with a body  weight ≥45 kg (99 lbs). This 
inclusion criterion will only  be assessed at the screening vis it and on Day  -1.
7.Willing and able to consume standardized meals during the confinement period of the study . 
All participants will be required to consume the identical meals on study  days when serial PK 
blood samples are collected
.
4.[ADDRESS_964227] y ear, per the investigator.
6.Donation of blood or blood products (eg, plasma or platelets) within [ADDRESS_964228]:
a.Have used an investigational product (if elimination half -life is <6 day s, otherwise 5 
half-lives).
b.Have been enrolled in a clinical study  (including vaccine studies) that, in the 
investigator’s opi[INVESTIGATOR_1649], may  impact this Shire -sponsored study .
8.Confirmed systolic blood pressure (BP) >139 mmHg or <89mmHg, and diastolic BP 
>89mmHg or <49 mmHg.
9.Twelve -lead ECG values demonstrating QTcF >450 msec (males) or >470 msec (females) at 
the screening visit or Day -1. If QTcF exceeds 450msec (males) or 470msec (females), the 
ECG should be repeated [ADDRESS_964229]’s eligibility .
10.Positive screen for drugs of abuse and/or disallowed drugs (ie, amphetamines, 
benzodiazepi[INVESTIGATOR_1651], barbiturates, cocaine, opi[INVESTIGATOR_858], phency clidine) at screening, or drugs of 
abuse or alcohol on Day  
-1. This screen will include marijuana.
11.Male subjects who consume more than 21 units of alcohol per week or 3 units per day. 
Female subjects who consume more than 14 units of alcohol per week or 2 units per day . One 
alcohol unit=1 beer or 1 wine (5 oz/150 mL) or 1 liquor (1.5 oz/40 mL) or 0.75 oz alcohol.
12.Positive HI V, HBsAg, or HCV antibody  screen.
13.Use of tobacco in any form (eg, smoking or chewing) or other nicotine -containing products 
in any form (eg, gum, patch, electroni c). Ex-users must report that they have stopped using 
tobacco for at least [ADDRESS_964230].
14.Routine consumption of more than 2 units of caffeine per day or subjects who experience 
caffeine withdrawal headaches . One caffeine unit is contained in the following items: one 
6oz (180 mL) cup of coffee, two 12 oz (360 mL) cans of cola, one 12oz cup of tea, and 
three 1oz (85g) chocolate bars. Decaffeinated coffee, tea, or cola are not considered to 
contain caffeine ).
15.Current use of any medication (including over-the-counter, herbal, or homeopathic 
preparations; with the exception of stable hormonal replacement therapy  or hormonal 
contraceptives). Current use is defined as use within [ADDRESS_964231]. See Section 5(Prior and Concomitant Treatment) for a list of permitted medications.
16.Abnormal laboratory  values considered clinically  significant, as determined by [CONTACT_1275], at screening or Day  -1.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_964232], as determined b y the investigator.
4.3 Restrictions
1.Subjects should refrain from strenuous phy sical exercise 48 hours prior to admission to the 
CRC and during the in-house stay s at the CRC. I n addition, subjects should refrain from 
strenuous phy sical exercise 30 minutes prior to all out- patient visits. 
2.Subjects should refrain from alcohol 48 hours prior to admission to the clinical research 
center (CRC) and during the in -house stay  at the CRC (Day s 1-5) and 48 hours prior to each 
outpatient visit during the study .
3.Subjects should refrain from the use of tobacco or any  products containing nicotine within 
30days of Day  1 of the treatment period.
4.Subjects should refrain from taking or regularl y using an y medication (including over -the 
counter multivitamin, herbal, or homeopathic preparations) with the exception of those listed 
in Section 5.2.[ADDRESS_964233]
through the completion of the discharge (assessments and procedures) from the CRC on 
Day 5.
5.
Subjects should refrain from foods or beverages containing caffeine/xanthine [ADDRESS_964234] should 
also refrain from foods or beverages containing caffeine/xanthine 30 minutes prior to all out -
patient visits.
6. Subjects will be required to follow standardized meal schedules and eat the meals provided 
by [CONTACT_709208] C RC. No outside food or beverages (including gum, mints, 
etc.) will be permitted. Menus will be identical for all subjects at the CRC. Copi[INVESTIGATOR_709201] . While 
confined, the total
daily nutritional composition should be approximately  50% carboh ydrate, 
35% fat, and 15% protein. The daily  caloric intake per subject should not exceed 
approximately  [ADDRESS_964235]. 
Female subjects should be either:
Postmenopausal (12 consecutive months of spontaneous amenorrhea and follicle stimulating 
For non-commercial use only
Shire CONFIDENTIAL Page 28
SHP643 -102 Protocol
Lanadelum ab 29 Jan 2019
hormone (FSH) result in the labora tory post -menopausal range at s creening)
Surgicall y sterile (having undergone one of the following surgical procedures: hy sterectom y, 
bilateral tubal ligation, bilateral oophorectom y or bilateral salpi[INVESTIGATOR_8820] y) and, at least, 
6weeks post -sterilization, or
Females of childbearing potential with a negative serum beta -human chorionic gonadotropin 
(-hCG) pregnancy  test at the screening 
visit and Day  -1. Females of childbearing potential 
must agree to abstain from sexual activity  that could result in pregnancy or agree to use 
acceptable methods of contraception.
Acceptable methods of contraception are:
Intrauterine devices plus condoms
Double
-barrier methods (eg, condoms and diaphragms with spermicidal gel or foam)
Hormonal contraceptives (oral, depot, patch, injectable, or vaginal ring), stabilized for at 
least [ADDRESS_964236], plus condoms. Note: If subject 
becomes sexually  active during the study , they  should use one of the other acceptable 
methods noted above in ad dition to the hormonal contraceptive until it has been stabilized for 
[ADDRESS_964237]. Acceptable methods of contraception for male subjects include:
Double- barrier methods (eg, condoms and diaphragms w ith spermicidal gel or foam).
4.[ADDRESS_964238] may  withdraw from the study  at any  time for an y reason without prejudice to his/her 
future medical care b y the physician or at the institution, or may  be withdrawn at any  time at the 
discr etion of the investigator or sponsor (eg, in the interest of subject safety ). The investigator is 
encouraged to discuss withdrawal of a subject with the medical monitor when possible.
If a subject discontinues from the study , regardless of the reason, the early  withdrawal 
evaluations listed in Table 1 are to be performed as completely  as possible. Whenever possible, 
all discontinued subjects should complete earl y termination procedures. Comments (spontaneous 
or elicited) or complaints made b y the subject mu
st be recorded in the source documents. The 
reason for discontinuation and date of discontinuation must be recorded in the source documents. 
Subjects who discontinue from the study  will not be replaced.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_964239]’s source document. I f a subject discontinued for more than 1 reason, each reason should 
be documented in the source document.
Reasons for discontinuation include but are not li mited to:
Adverse event
Protocol violation
Withdrawal by  [CONTACT_1130] 
Lost to follow -up
Other
4.5.2 Subjects ‘Lost to Follow -up’ Prior to Last Scheduled Visit
A minimum of [ADDRESS_964240] (office visit or telephone contact). At least [ADDRESS_964241]’s last 
known address via courier or mail (with an acknowledgement of receipt request) asking that they  
return to the site for final safet y evaluations. 
For non-commercial use only
Shire CONFIDENTIAL Page 30
SHP643 -102 Protocol
Lanadelum ab 29 Jan 2019
5. PRIOR AND CONCOMITAN T TREATMENT
5.1 Prior Treatment
Prior treatment includes all treatment (including but not limited to herbal treatments, vitamins, 
and nonpharmacological treatments such as p sychotherap y received within 30 days [or PK 
equivalent of 5 half -lives, whichever is longer]) of the date of dose of investigational product. 
Prior treatment information must be recorded on the appropriate CRF page.
5.[ADDRESS_964242] and the end of the follow -up period (ie, Day  112/e nd of s tudy visit), 
inclusive.  Concomitant treatment information must be recorded on the appropriate CRF page.
5.2.1 Permitted Treatment
Subjects should refrain from taking an y medications (excluding those medications listed below) 
during the course of the study . Any medication which is considered necessary for the subject’s 
safet y and wellbeing may be given at the discretion of the investigator. The administration of all 
concomitant medications must be listed on the appropriate CRF page.
Medications permitted during the stud y are listed below:
Hormonal contraceptives for females of child -bearing potential admini stered according to the 
package insert (see Section 
4.4.1)
Hormone replacement therap y ≥[ADDRESS_964243]
Occasional use of nonsteroidal anti-inflammatory  drug as prescribed by [CONTACT_1961] [INVESTIGATOR_9232].
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_964244] is lanadelumab (SHP643, formerly known as DX -2930), which will be provided 
for each subject as either a 300 mg/dose PFS or a 300 mg/dose AI for SC injection. Additional 
information abou t lanadelumab is provided in the current lanadelumab Investigator’s Brochure.
6.1.[ADDRESS_964245] will be randomized to receive either a single 300 mg lanadelumab SC injection in the 
abdomen administered via PFS or a s ingle 300 mg lanadelumab SC injection in the abdomen 
administered via AI on Day  1 of the in -house confinement period. The start and stop times (to 
the nearest second) for IP injection (both PFS and AI) will be recorded in subject source 
documentation and t
he CRF. 
A full description of the details for the preparation and administration of the investigational 
product and of the devices for administration will be provided in a separate Pharmacy  Manual.
6.2.[ADDRESS_964246] is labeled with a minimum of the protocol number, dosage form 
(including product name), directions for use, storage conditions, expi[INVESTIGATOR_709202] (if applicable), 
Lot number and/or packaging reference, the statements “For clinical trial use only ” and/or 
“CAUTION: New Drug –Limited by  [CONTACT_4496] (or US) Law to Investigational Use,” and “Keep 
out of reach of children,” and the sponsor’s name [CONTACT_3816] .
Space is allocated on the label so that the site representative can record a unique subject 
identifier and initials. 
Additional labels (eg, those used when dispensing mark eted product) may , on a case- by-case 
basis, be applied to the investigational product in order to satisfy  local or institutional 
requirements, but must not:
Contradict the clinical study  label
Obscure the clinical study label
Identify  the study  subject by  [CONTACT_10178]’s prior full agreement.
6.3.[ADDRESS_964247]/nominated 
team member will enter the unique subject identifier and initials on the investigational product 
bottle/carton labels as they are distributed.
Investigational produc t must be stored in accordance with labeled storage conditions. 
Temperature monitoring is required at the storage location to ensure that the investigational
product is maintained within an established temperature range. The investigator is responsible 
forensuring that the temperature is monitored throughout the duration of the study  and that 
records are maintained; the temperature should be monitored continuously  by [CONTACT_3570]-house sy stem, a mechanical recording device such as a calibrated chart recorder, or b y manual 
means, such that both minimum and maximum thermometric values over a specific time period 
can be recorded and retrieved as required. Such a device (ie, certified min/max thermometer) 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_964248](s), eg, fumigation of a 
storage room.
6.3.4 Special Handling
Refer to the SHP643- 102 Pharmacy  Manual for complete details regarding the lanadelumab 
(SHP643) investigational product and devices.
6.[ADDRESS_964249] dispensed, used, returned, and/or destroy ed must be 
maintained as detailed further in this section .
The investigator has overall responsibility  for administering investigational product.  Where 
permissible, tasks may  be delegated to a qualified designee (eg, a pharmacist) who is adequatel y 
trained in the protocol and who works under the direct supervision of the investigator.  This 
delegation must be documented in the applicable study  delegation of authority  form.
The investigator or his/her designee (as documented by  [CONTACT_49121] y form) will administer the investigational product only to subjects 
included in this study  following the procedures set out in the study  protocol. Each subject will be 
given onl y the investigational product carry ing his/her treatment assignment. All administr ations 
of IP
will be documented in the subject's source and/or other investigational product record. 
No investigational product stock or returned inventory  from a Shire -sponsored study  may  be 
removed from the site where originall y shipped without prior knowledge and consent b y the 
sponsor.  If such transfer is authorized by  [CONTACT_456], all applicable local, state, and national 
laws must be adhered to for the transfer.
The sponsor or its representatives must be permitted access to review the supplies stora ge and 
distribution procedures and records .
At the end of the stud y, or as instructed b y the sponsor, all unused stock, and empty /used 
investigational product packaging are to be sent to a nominated contractor on behalf of the 
sponsor. I nvestigational product s being returned to the sponsor’s designated contractors must be 
counted and verified b y clinical site personnel and the sponsor (or designated CRO). For unused 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_964250] be signed prior to shipment from the site. 
Validated electronic return sy stems (ie, IRT) do not require a shipment f orm. Returned 
investigational products must be packed in a tamper -evident manner to ensure product integrit y. 
Contact [CONTACT_10181]. 
Shipment of all returned investigational product must comply  with local, state, and natio nal laws.
Based on entries in the site drug accountability  forms, it must be possible to reconcile 
investigational products delivered with those used and returned.  All investigational products 
must be accounted for and all discrepancies investigated and documented to the sponsor’s 
satisfaction.
6.[ADDRESS_964251] be assessed by  [CONTACT_363587]. The 
investigator/nominated person will record details on the drug accountability  log(s) and/or source 
documents. In addition, details of the dosing will be captured in the appropriate CRF.
6.6 Retention of Bioavailability and Bioequivalence Testing Samples
In compliance with 21 CFR 320.38 (1999), and as recommended in the Center for Drug 
Evaluation and Researc h Guidance for Industry  dated May  2004 regarding retention of relevant 
reserve (BA and BE test samples), CROs, site management organizations, or clinical 
investigators must retain samples when relevant BA/BE testing has been performed under 
contract b y the sponsor.  Retained samples must meet 21 CFR 320.38 (1999) and 320.63 (1999) 
requirements for reserve samples of test article and reference standards according to the 
following:
Reserve samples must be representative of the test batches provided and theref ore must be 
randomly  selected from identical test article and/or reference standards provided to the site
The quantity of retained samples should be sufficient optimally  to permit the FDA to perform 
all release testing identified in the application 5 times
Samples are adequatel y identified so that the reserve sample can be positively  identified as 
having come from the same batches as used in the BA/BE studies
Samples must be stored under conditions that maintain the identity , integrit y, strength, 
quality , and purit y of the samples.
Samples must be retained for at least [ADDRESS_964252] 5 y ears following the date of completion of the BA/BE study
Samples must be annually inspected and documented to confirm integrity .
For non-commercial use only
Shire CONFIDENTIAL Page 35
SHP643 -102 Protocol
Lanadelum ab 29 Jan 2019
7. STUDY PROCEDURES
7.1 Study Schedule
See Table 1, Table 2, and Table 3for stud y procedures.  
The following “priority order” will be in effect when more than 1 procedure or assessment are 
required at a particular time point.
Spontaneous or solicited AE reporting
Electrocardiogram (ECG)
Vital signs
Clinical laboratory  tests
Pharmacokinetic blood sampling
Anti- drug antibody  (ADA) sampling
Physical examination.
NOTE: Blood sampling for PK evaluation must be performed at the precise protocol -scheduled 
time. Actual sampling time(s) must be accurately recorded in the source document and 
appropriate CRF.
7.1.[ADDRESS_964253] for their records.
[IP_ADDRESS] Screening Failure
A screen failure is a subject who has given informed consent and failed to meet the inclusion 
and/or met at least [ADDRESS_964254].
[IP_ADDRESS] Rescreening of Subjects
Subjects who fail to meet all inclusion/exclusion criteria will not be permitted to be rescreened 
for the stud y at an y point.
Eligible subjects who meet all inclusion/exclusion criteria, but are unable to participate in the 
study  due to scheduling conflicts/timing, may  be rescreened based on investigator discretion and 
sponsor approval should their availability  to participate fall outside the screening window.  In
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_964255] be signed.
7.1.2 Treatment Period 
[IP_ADDRESS] In-house Confinement Period (Day 1 to Day 5)
Study  assessments for Day  [ADDRESS_964256] will occur on study  Day  1 (for 
all study  subjects) of the in
-house confinement treatment period.
Subjects will be discharged from the CRC following completion of the last study  assessment on 
Day 5 of the in -house confinem ent period.
[IP_ADDRESS] Out-Patient Visit Period (Day 7 -112) 
The out -patient visit period for this protocol begins following discharge on Day  [ADDRESS_964257] out -patient visit (Day  112 ± 3 day s). The first out -patient visit is on Day  7. During 
this out -patient period, subjects will return to the CRC for 8 visits in order to complete scheduled 
assessments and procedures (as detailed in Table 3).
These assessments include: blood and urine samples for clinical
 safet y labs including pregnancy 
testing for al l females, blood samples for PK assessments, urine for drug and alcohol testing, 
physical examination (including weight), vital signs (including BP, pulse, and oral body  
temperature), ECG, serious adverse events (SAEs), AEs, blood samples for ADA assessmen ts 
and concomitant medications.
[IP_ADDRESS] Final Visit (Day 112)
The final visit will be the Day  112 (± 3 day s) out -patient visit.  This visit also serves as the 
follow -up visit for this study .  Refer to Table 1and Table [ADDRESS_964258] study  visit (Day  112) will be 
followed until closure (see Appendix 4 .2).
7.1.3
Additional Care of Subjects After the Study
No after care is planned for this study .
7.2 Study Evaluations and Procedures
7.2.1 Demographic and Other Baseline Characteristics
Date of birth
Sex
Race and ethnicity
7.2.[ADDRESS_964259] part y vendor (eg, clinical laboratory ) used in this stu dy will 
be maintained in the investigator’s and sponsor’s files.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_964260]'s source 
documentation. The sponsor’s expectation is that the investigator will ensure that every  effort is 
made t o perform all assessments at the precise protocol- scheduled time. Any  safet y assessment 
that deviates from the scheduled assessment time set forth in the protocol by  [CONTACT_726] [ADDRESS_964261] signs the informed consent form to completion of the 
study  (including to time of screen failure or drop out/discontinuation).  Du ring the stud y, subject 
safet y will be closel y monitored by [CONTACT_363588], ECG measurements, clinical safet y 
labs, and ph ysician oversight
[IP_ADDRESS] Medical and Medication History
A complete medical and medication history  will be performed at the screening visit/time points 
described in 
Table 1by a qualified licensed ph ysician, phy sician’s assistant, or a nurse 
practitioner.  The medical history  will be reviewed and recorded, including:
Recent ingestion of medication (30 day s prior to entering the s creening period)
History  of respi[INVESTIGATOR_696], cardiovascular, renal, gastrointestinal, hepatic, endocrine, 
hematological, neurological, psy chiatric, and other diseases
Smoking habits. 
[IP_ADDRESS] Physical Examination (Including Height and Weight)
A complete ph ysical exam
ination will be performed at the time points described in Table 1, 
Table 2, and Table 3 by a qualified licensed ph ysician, phy sician’s assistant, or a nurse 
practitioner.
The phy sical examination will include a review of the following bod y systems:
General appearance
Skin
Head, ey es, ears, nose, and throat
Spi[INVESTIGATOR_050]/neck/thy roid
Musculoskeletal
Respi[INVESTIGATOR_696]
Cardiovascular
Neurological
Abdomen (including liver and kidney s)
Clinically  significant (per investigator) abnormalities identified at the screening visit w ill be 
documented in the subject’s source documents and on the medical history  CRF. Changes 
For non-commercial use only
Shire CONFIDENTIAL Page 38
SHP643 -102 Protocol
Lanadelum ab 29 Jan 2019
(worsening in frequency  or severit y) after the screening visit will be captured as AEs on the AE 
CRF page, as deemed b y the investigator.
[IP_ADDRESS] Adverse Event Collection
At each stud y visit, subjects will be questioned in a general way to ascertain if AEs have 
occurred since the previous visit (eg, “Have you had an y health problems since your last visit?”). 
Adverse events are collected from the time informed consent is sign ed. (Refer to Appendix 4 for 
AE definitions, assessment, collection time frame, and reporting procedures.)
[IP_ADDRESS] Vital Signs
Blood Pressure and Pulse Rate
Blood pressure and pulse rate will be measured at times specifi
ed in Table 1, Table 2, and Table 
3of this
protocol. Additional blood pressure and pulse rate measurements may  be performed, as 
determined b y the investigator, in order to ensure appropriate monitoring of subject safety and 
accurate recording of vital sign measurements. Any  changes from baseline w hich are deemed 
clinically  significant b y the investigator are to be recorded as an AE.
The same method for obtaining blood pressure measurement (auscultatory  or oscillometric) 
should be used throughout the study  for all subjects (and documented).  In addition, the 
conditions of vital sign measurements should be controlled and as consistent as possible during 
the study , in order to minimize external variability of the readings.  It is advised that 
measurements be collected at a comfortable room temperature with little to no background noise, 
using the same (appropriately sized) cuff placed at the same location of the same arm during the 
study .  The bladder deflation rate should be deflated (calibrated for oscillometric method or 
manually  by [CONTACT_444101]) at a rate of 2 -3 mmHg/s (and the first and last audible sounds 
recorded as s ystolic and diastolic pressure) after at least [ADDRESS_964262] a bladder length that is 80% and a width that is at least 40% of arm 
circumference (a length -to-width ratio of 2:1).  
The subject should be asked to remove all clothing that covers the location of cuff placement. 
The subject should not have exercised or consumed caffeine, alcohol, or nicotine within the time 
frame( s) outlined in the Restrictions Section 4.3. The subject should be instructed to relax as 
much as possible for at least [ADDRESS_964263] should be l ying comfortabl y, with the legs uncrossed.  The arm should be supported 
with a pi[INVESTIGATOR_6356], such that the middle of the cuff on the upper arm is at the level of the right atrium 
(approximately  halfway  between the bed and the level of the sternum) .
At the s creening visit, blood pressure should be compared between both arms.  When there is a 
consistent inter
-arm difference confirmed over 3 consecutive measurements (>10 mmHg), the 
arm with the higher blood pressure should be used for inclusion at screening and the last 
For non-commercial use only
For non-commercial use only
Shire CONFIDENTIAL Page 40
SHP643 -102 Protocol
Lanadelum ab 29 Jan 2019
indicating if the value(s) is/are not clinically  significant or clinicall y significant. Abnormal 
clinical laboratory values, which are unexpected or not e xplained by  [CONTACT_423]’s clinical 
condition, may , at the discretion of the investigator or sponsor, be repeated as soon as possible 
until confirmed, explained, or resolved.
The following clinical laboratory  assessments will be performed: 
Biochemistry
Blood samples (8.5 mL) for serum biochemistry  will be collected into a red gel separator tube at 
the time points described in Table 1, Table 2, and Table 3.  The following parameters will be 
assessed:  
Sodium Phosphorus -hCGb
Potassium Total protein FSHb
Glucose Total CO 2(Bicarbonate)
Blood urea nitrogen Albumin
Creatinine Aspartate transaminase 
Calcium Alanine transaminase 
Chloride Gamma glutamy l transferase 
Thyroid stimulating hormone (TSH)aAlkaline phosphatase 
Thyroxine (T4 total)aTotal bilirubin 
Triiodothy ronine (T3)aUric acid
a Collected at screening only.
bFemales only (Please refer to Table 1, Table 2, and Table 3for collection time -points).
Hematology
Blood samples (4 mL) for hematology  will be collected into a K 2-EDTA tube at the time points 
described in Table 1, Table 2, and Table 3.  The following parameters will be assessed:
Hemoglobin Total neutrophils (absolute)
Hematocrit Eosinophils (absolute)
Red blood cells Monocy tes (absolute)
Platelet count Basophils (absolute)
White blood cell count; total and differential Lym phocy tes (absolute)
For non-commercial use only
Shire CONFIDENTIAL Page 41
SHP643 -102 Protocol
Lanadelum ab 29 Jan 2019
Coagulation
Blood samples (2.7 mL) for coagulation will be collected into a sodium citrate tube at the time 
points outlined in Table 1, Table 2, and Table 3. The following parameters will be assessed:
PT PTT INR
Urinalysis
A urine sam ple for urinaly sis will be collected at the time points described in Table 1, Table 2, 
and Table 3.  The following parameters will be assessed:
pH Blood Nitrites
Glucose Ketones Leukocy te 
esterase
Protein Bilirubin Specific gravit y
Microscopic examination will be conducted if protein and/or blood is/are detected during 
urinaly sis.  At a minimum the microscopic examination will consist of red blood cells, white 
blood cells, casts, and bacteria. 
[IP_ADDRESS] Pregnancy Test
A serum -hCG pregnancy test will be performed on all females at the time points outlined in 
Table 1, Table 
2, and Table 3or on withdrawal of the subject from the study .
[IP_ADDRESS] Drug and Alcohol Screen
A urine screen for drugs of abuse and alcohol (breath test) will be performed at the time points 
described in Table 1, Table 2, and Table 3.  This screen will include marijuana. Additional drug 
and alcohol screens may  be performed at the investigator’s discretion.
Urine samples are to be tested for amphetamines, barbiturates, benzodiazepi[INVESTIGATOR_1651], cannabinoids, 
cocaine, methadone, opi[INVESTIGATOR_10149], and phencyclidine.
Results of urine drug and alcohol screens will be reviewed and verified b y the study monitor but 
will not be collected in the CRF database.
Any positive result for drugs of abuse or alcohol at screening or on Day  -[ADDRESS_964264] the s
ponsor’s Medical Monitor to discuss and 
review the circumstances and to determine whether the subject may  continue in the study . 
Details of the discussion taken must be properl y recorded in the subject’s source documents.
For non-commercial use only
Shire CONFIDENTIAL Page 42
SHP643 -102 Protocol
Lanadelum ab 29 Jan 2019
[IP_ADDRESS] Serology Screen 
At the s creening visit, a blood sample of approximately  8.5mL will be drawn into a serum 
separator tube to test for the presence of HIV, HBsAg, and HCV antibod y.
The test results must be confirmed negative prior to enrollment in the study.  If a test result is 
positive, the subject will be excluded from entering the stud y.  Results of the virology  screen will 
be reviewed and verified by  [CONTACT_10184], but will not be collected in the CRF database.
[IP_ADDRESS] Electrocardiogram 
Twelve -
lead ECGs will be performed at the t imes specified in Table 1, Table 2, and Table 3.  All 
ECGs will be performed using the equipment supplied by  [CONTACT_10186].  
The following parameters will be recorded on the appropriate CRF page: heart rate, PR, RR, 
QRS, and QT intervals (QTcF) will be derived from the data in the database.  The investigator’s 
assessment of the ECG tracing as normal or abnormal must be documented, and if abnormal, 
his/her determination of whether the abnormalit y is clinically  significant or not, will be 
documented on the tracing and recorded in the CRF.
The subject should be asked to remove all clothing that covers the location of lead placement.  
The subject should not have exercised or consumed caffeine, alcohol, or nicotine within the 
timeframe outlined in the Restrictions Sec tion 4.3. The subject must be resting in the supi[INVESTIGATOR_12473] [ADDRESS_964265]’s baseline ECG.
To ensure safet y of the subjects, a qualified individual at the investigator site will make 
comparisons to baseline measurements.
If the QTcF interval (calculated on line on site) is increased b y >45 msec from the baseline, or an 
absolute QTcF value is >500 msec for an y scheduled ECG, then 2 additional ECGs will be 
collected, approximately  2-4 minutes apart, to confirm the original measurement.  If either of the 
QTcF values from these repeated ECGs remains above the threshold value (>45 msec from the 
baseline; or is >500 msec), then a single ECG must be repeated at least hourly  until QTcF values 
from 2 successive ECGs fall below the threshold value that triggered the repeat measurement.  
If QTcF values remain above 500 msec (or >45 msec from the baseline) for >4 hours (or sooner 
at the discretion of the investigator); or QTcF intervals get progressively  longer, the subject 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_964266] should be consulted if QTcF 
intervals do not return to <500 msec (or to <45 msec above the baseline) after 8 hours of 
monitoring (or sooner at the discretion of the investigator).
If a machine -read QTcF value is prolonged, as defined above, repeat measurements may  not be 
necessary  if a qualified phy sician’s interpretation determines that the QTcF values are in the 
acceptable range.
7.2.3 Pharmacokinetic Procedures
The name [CONTACT_10214] (ies) for this study  will be maintained in the 
investigator’s files at the/each site and in the Trial Master File at the CRO.
Actual pharmacokinetic blood sample collection times versus time of dosing will be monitored. 
The sponsor's expectation is that th e investigator will ensure that every  effort is made to collect 
all pharmacokinetic blood samples at the precise protocol scheduled time. Pharmacokinetic 
blood collection must not deviate from the nominal collection time set forth in the protocol by 
[CONTACT_227139] t han [ADDRESS_964267]- dose or b y more than  [ADDRESS_964268] -dose on Day  1 through Day  5 onl y. Samples 
drawn outside these parameters will be considered a protocol deviation. 
[IP_ADDRESS] Blood Sample Collection and Handling Procedures
Blood samples will be collected at the time specified in Table [ADDRESS_964269] be freezer -safe and 
identified with freezer -safe labels provided b y the CRC. The labels will contain the following 
information:
Study  number
Subject identifier
Nominal day
Nominal time
Matrix identifier (plasma)
Split (primary  or backup)
[IP_ADDRESS] Shipment of Plasma, Pharmacokinetic Samples
Instructions for shipment of all PK samples (along with the corresponding documentation) can 
be found in the laboratory  manual. 
Pharmacokinetic samples will be stored nominally at -70°C (±10°C) prior to and after anal ysis at 
the CRO until further directions are authorized by [CONTACT_10188].
For non-commercial use only
Shire CONFIDENTIAL Page 44
SHP643 -102 Protocol
Lanadelum ab 29 Jan 2019
[IP_ADDRESS] Plasma Drug Assay Methodology
Plasma concentrations will be measured using the most current validated bioanal ytical method. 
In add ition, selected plasma samples may  be used to investigate incurred sample reproducibility  
(full details will be described in the bioanal ytical study  plan). The presence of other metabolites 
or artifacts may  be assessed or quantified as appropriate. Raw data will be stored in the archive 
of the designated bioanaly tical contract laboratory.
[IP_ADDRESS] Immunogenicity Testing for Anti -Drug Antibodies
The name [CONTACT_363595] y testing 
for this study  will be maintained in the investigator’s files at the study  site and in the Trial 
Master File at the CRO.
Actual ADA blood sample collection times versus time of dosing will be monitored. The 
sponsor’s expectation is that the investigator will ensure that every  effort is made to collect all 
anti-
drug blood samples at the precise protocol scheduled time. Anti- drug antibody  blood 
collection will be collected on Day  1 prior to dose within 60 minutes of dose). See Table 2and 
Table [ADDRESS_964270], the investigator 
will be notified by  [CONTACT_181880]. I t will be the investigator’s responsibility  to notify  the subject. 
7.2.[ADDRESS_964271]
Table 4: Volume of Blood to Be Drawn from Each Subject
Assessment Sample Volume (mL)Number of 
SamplesTotal Volum e (mL)
Pharm acokinetic samplesa5 14 70
HBsAg, HIV, HCV 5 1 5
Safety Biochemistry, FSH 
and -hCGa,b,c8.5 12 102
Hem atology 4 12 48
Coagulation
(PT, aPTT, INR)2.7 11 29.7
Anti-drug Antibody samples 3 5 15
Total mL 269.7
-hCG=beta -human chorionic gonadotropin; FSH=follicle stimulating hormone; HBsAg=hepatitis B surface antigen; 
HCV=hepatitis C virus; HIV=human immunodeficiency virus; TSH=thyroid stimulating hormone; T3=triiodothyronine; 
T4= thyroxine
aIf a catheter is used for any blood draw or series of blood draws, then the first [ADDRESS_964272] 
has been taken into account in the table above and the total blood volume required for this study.
b-hCG and FSH testing for females only.
cTSH , T3 and T4 will be included in the biochemistry panel, and collected at screening only .
For non-commercial use only
Shire CONFIDENTIAL Page 45
SHP643 -102 Protocol
Lanadelum ab 29 Jan 2019
During this stud y, it is expected that approximately 269.7 mL of blood will be drawn from all 
subjects, regardless of sex.
Note: The amount of blood to be drawn fo r each assessment is an estimate. The amount of blood 
to be drawn may  vary  according to the instructions provided by  [CONTACT_10190]; however, the total volume drawn over the course of the stud y 
should be approxi mately  269.7 mL. When more than 1 blood assessment is to be done at the time 
point/period, if they  require the same t ype of tub e, the samples may  be combined.
For non-commercial use only
Shire CONFIDENTIAL Page 46
SHP643 -102 Protocol
Lanadelum ab 29 Jan 2019
8. DATA MANAGEMENT AND STATISTICAL METHODS
8.1 Data Collection
The investigator’s authorized site person nel must enter the information required by  [CONTACT_709209].  This study will be monitored 
according to ICH GCP Guidelines. 
A study  monitor will visit the site in accordance with the monitoring plan and review the CRF 
data against the source data for completeness and accuracy. Discrepancies between source data 
and data entered on the CRF will be addressed b y qualified site personnel. When a data 
discrepancy  warrants correction, the correction will be made b y authorized site personnel. Data 
collection procedures will be discussed with the site at the site initiation visit.  Once a subject is 
randomized, it is expected that site personnel will complete the CRF entry  within approximately  
[ADDRESS_964273]’s visit.
8.2 Clinical Data Management
Data are to be entered into a clinical database as specified in the CRO’s data management plan
and according to the study  CRF Completion Guidelines .  Quality  control and data validation 
procedures are applied to ensure the validity  and accuracy  of the clinical database.
Data are to be reviewed and checked for omissions, errors, and values requiring further 
clarification using computerized and manual procedures.  Data queries requiring clarification are 
to be c ommunicated to the site for resolution.  Only  authorized personnel will make corrections 
to the clinical database, and all corrections are to be documented in an auditable manner.
8.3 Data Handling
All analy ses/summaries will be based on observed data, with no imputation for missing data, 
unless otherwise specified in the statistical analysis plan (SAP).
8.4 Statistical Analysis Process
The study
 data will be analy zed by  [CONTACT_10196].
Unless otherwise specified, summary  tabulations will be presented by  [CONTACT_1570]. For 
categorical variables, the number and percentage of subjects within each category  (with a 
category  for missing data as needed) of the parameter will be presented. For contin uous 
variables, the number of subjects, mean, median, standard deviation (SD), minimum, and 
maximum values will be presented. The SAP will provide the statistical methods and definitions 
for the analy sis of the pharmacokinetic, and safety data, as well as describe the approaches to be 
taken for summarizing other study  information such as subject disposition, demographics and 
baseline characteristics, investigational product exposure, and prior and concomitant 
medications.  The SAP will also include a descri ption of how missing, unused and spurious data 
will be addressed. 
For non-commercial use only
Shire CONFIDENTIAL Page 47
SHP643 -102 Protocol
Lanadelum ab 29 Jan 2019
To preserve the integrit y of the statistical anal ysis and study  conclusions, the SAP will be 
finalized prior to database lock.
Pharmacokinetic analyses will be performed using Phoenix® WinN onlin® (Certara, Princeton, 
NJ [ZIP_CODE]) . All other statistical anal yses will be performed using SAS(SAS I nstitute, Cary , NC 
[ZIP_CODE]). 
8.5 Planned Interim Analysis, Adaptive Design, and Data Monitoring Committee
There are no planned interim analy sis, adaptive de sign, or DMC in this study.
8.6 Sample Size Calculation and Power Considerations
The planned sample size for this study  is approximately  176 subjects; 88 subjects in the PFS arm 
and 88 subjects in the AI arm. The sample size was calculated using SAS v9.3 based on the two 
one-sided tests procedure of Schuirmann on the log -transformed data.
Considering a parallel group design and assuming a total variability of 40% for C max(expected to 
be larger than the total variability  for AUC) and a true ratio of test/refere nce of 100%, 
equivalence between test and reference in their bioavailability  based on the acceptance interval 
of 80.00 to 125.00% can be demonstrated with a power of 90% and a t ype I error of 5% based on 
66 subjects per group (132 subjects in total). To account for up to 25% potential drop outs and/or 
non-reliable concentration time -profiles, approximately  88 subjects per group (176 in total) need 
to be randomized to ensure that at least [ADDRESS_964274] anal ysis sets, as defined:
The randomized set will consist of all subjects randomized to an administration ty pe 
group .
Safety  analysis set: All subjects who received the dose of lanadelumab (study  drug). The 
safety analysis setwill be used for the anal ysis of safet y endpoints
Pharmacokinetic (PK) analysis set: All randomized subjects who received the dose of 
lanadelumab and have sufficient data to calculate at least 1 primary  PK endpoint [AUC 0-
last, AUC 0-∞ or C max]. Subjects must not have protocol deviations that would impact data 
analysis.The PKanalysis setwill be used for the anal ysis of PKendpoints.
8.8 Analysis of Disposition
The numbers of subjects randomized, completing, or withdrawing, along with reasons for 
withdrawal, will be tabulated b y treatment group and overall for the randomized set, safety  
analysis set, and pharmacokinetic analysis set.
For non-commercial use only
Shire CONFIDENTIAL Page 48
SHP643 -102 Protocol
Lanadelum ab 29 Jan 2019
8.9 Demographics and Baseline Characteristics Analyses
Baseline and demographic variables will be descriptively  summarized by  [CONTACT_709210] s afety analysis set, and PK analysis set.
8.10 Treatment Compliance and Extent of Exposure
It is anticipated that all patients will be compliant with treatment because the study  medication 
will be administered in the clinic .  The extent of exposure to study  drug will be described by 
[CONTACT_709211] 1 injection for the safety analysis 
setand PKanalysis set.
8.11 Pharmacokinetic Analyses
Pharmacokinetic anal yses will be performed for the subjects in the PKanalysis set.
8.11.1 Pharmacokinetic Analysis
Pharmacokinetic parameters will be calculated using plasma conc entration -time data by  
[CONTACT_105]-compartmental methods, and all calculations will be based on actual sampling times. 
Baseline is defined as the Day  1 pre -
dose concentration. Pharmacokinetic parameters will be 
estimated by  [CONTACT_105]- compartmental analy sis and will incl ude, but not be limited to, the following:
Cmax: Maximum observed plasma drug concentration
tmax: Time to reach C maxin plasma
AUC 0-last: Area under the concentration -time curve from time zero to the last quantifiable 
concentration in plasma
AUC 0-∞: Area u nder the concentration- time curve from time zero extrapolated to infinity
  z:Terminal elimination rate constant
t½:Terminal half -life
CL/F: Apparent clearance
Vdz/F: Apparent volume of distribution
Body weight -adjusted AUC 0-last, Cmax, CL/F, and Vdz/F will be estimated as well.
[IP_ADDRESS] Statistical Analysis of Pharmacokinetic Parameters
Pharmacokinetic parameters of lanadelumab and plasma concentrations at each nominal 
sampling time will be provided in subject data listing(s) and summarized using descriptive 
statistics (number of subjects, arithmetic mean, SD, coefficient of variation [CV%], median, 
minimum, maximum, geometric mean, and %CV of geometric mean). In addition, 95% 
confidence intervals for key  PK parameters will be provided as appropriate, as well as graphs of 
individual and mean (± SD) concentration -time profiles plasma lanadelumab and graph(s) of 
observed and weight -adjusted PK parameters (y -axis) versus body  weight (x -axis). 
For non-commercial use only
Shire CONFIDENTIAL Page 49
SHP643 -102 Protocol
Lanadelum ab 29 Jan 2019
All plasma concentration values below the lower limit of quantification (L LOQ) will be set to 
zero when calculating summary statistics. For the calculation of PK parameters, all plasma 
concentrations that are below LLOQ prior to the first measurable concentration will be set to 
zero. The LLOQ values below LLOQ that are between m easurable concentrations will be set to 
missing. The values below LLOQ values following the last quantifiable timepoints will be set to 
missing. No concentration estimates will be imputed for missing sample values. Any  sample 
with a missing value will be t reated as if the sample had not been scheduled for collection and 
will be ignored when calculating mean concentrations or PK parameters. 
Pharmacokinetic anal ysis will be based on the Pharmacokinetic population. 
8.12 Safety Analyses
Safety  anal yses will be per formed for the subjects in the safety analysis set. Safety  endpoints are 
defined in the Sy nopsis section.  Descriptive anal ysis, as described in Section 8.4will be 
performed to evaluate all safet y endpoints.
Adverse events will be coded using the Medical Dictionary  for Regulatory  Activities 
(MedDRA). Treatment -emergent AEs (TEAEs) are defined as AEs with onset at the time of or 
following the start of treatment with study  medication, or medical conditions present prior to the 
start of treatment but increasing in severit y or relationship at the time of or following the start of 
treatment. The number and percentage of subjects with TEAEs will be calculated overall, by  
[CONTACT_9313] (SOC), preferred term, and treatment group. Number and percentage of 
subje cts with TEAEs will be further summarized by  [CONTACT_11370] y and relationship to investigational 
product. Subjects with TEAEs related to investigational product, AEs leading to withdrawal, 
SAEs, and deaths will be similarly  summarized/listed.
Only  TEAEs will be analy zed.  All AEs (TEAEs and non- TEAEs) will be provided in the AE 
subject listings.  All safety  data, including derived data, will be presented in subject data listings, 
and all listings will include subject’s sex, age, race, weight and bod y mass index.
Actual values and change from baseline in clinical laboratory  tests and vital signs will be 
summarized by  [CONTACT_6982]. Potentially  clinicall y important findings will also be 
summarized or listed.
The number and percentage of subjects with nor mal, abnormal -not clinically significant, and 
abnormal -clinicall y significant ECG findings will be summarized by  [CONTACT_6982]. 
Abnormal ECG findings will be summarized or listed.
The number and percentage of subjects with neutralizing antibody , positive, negative, or not 
evaluable antibody  results will be summarized for each treatment group b y visit and overall. 
Positive immunogenicity results will be summarized or listed.
Concomitant medications will be coded using the World Health Organization- Drug Dictionary  
(WHO -DD). Concomitant medications are medications that the subject started or continued 
using a fter the study  medication administration.  Number of subjects with concomitant 
medications will be summarized by  [CONTACT_18671], preferred t erm, and treatment group.
For non-commercial use only
For non-commercial use only
Shire CONFIDENTIAL Page 51
SHP643 -102 Protocol
Lanadelum ab 29 Jan 2019
9. REFERENCES
By[CONTACT_281998], A. 2009. Hereditary  angio-oedema in Denmark: a nationwide survey . The British 
journal of dermatology, 161, 1153-8.
Goring, H. D., Bork, K., Spath, P. J., Bauer, R., Ziemer, A., Hintner, H. & Wuthrich, B. 1998. 
Hereditary angioedema in the German
-speaking region. Hautarzt, 49,114-22.
Lei, W. T., Shyur, S. D., Huang, L. H., Kao, Y. H. & Lo, C. Y. 2011. Type I hereditary 
angioedema in Taiwan --clinical, biological features and genetic study. Asian Pac J 
Allergy Immunol, 29,327- 31.
Nordenfelt, P., Dawson, S., Wahlgren, C. F., Lindfors, A., Mallbris, L. & Bjorkander, J. 2014. 
Quantify ing the burden of disease and perceived health state in patients with hereditary 
angioedema in Sweden. Allergy Asthma Proc, 35,185-90.
[COMPANY_002], O., Blanch, A., Caballero, T., Sastre, N., Callejo, D. & Lopez -Trascasa, M. 2005. 
Hereditary  angioedema due to C1 inhibitor 
deficiency : patient registry  and approach to 
the prevalence in Spain. Ann Allergy Asthma Immunol, 94,498-503.
Zuraw, B. L. 2008. Clinical practice. Hereditary  angioedema. N Engl J Med, 359, 1027 -36.
For non-commercial use only
Shire CONFIDENTIAL Page 52
SHP643 -102 Protocol
Lanadelum ab 29 Jan 2019
10. APPENDICES
For non-commercial use only
For non-commercial use only
For non-commercial use only
Shire CONFIDENTIAL Page 55
SHP643 -102 Protocol
Lanadelum ab 29 Jan 2019
APPENDIX 3 REGULATORY, ETHICAL, AND STUDY OVERSIGHT 
CONSIDERATIONS
For non-commercial use only
Shire CONFIDENTIAL Page 56
SHP643 -102 Protocol
Lanadelum ab 29 Jan 2019
APPENDIX 3.1 REGULATORY AND ETHIC AL CONSIDERATIONS
This study  is conducted in accordance with current applicable regulations including ICH E6, EU 
Directive 2001/20/EC, and all updates, as well as local ethical and legal requirements. 
Compliance with the se regulations and guidelines also constitutes compliance with the ethical 
principles described in the Declaration of Helsinki.
The name [CONTACT_10215] -party vendor (eg, CRO) used in this study  will be maintained 
in the investigator’s and sponso r’s files, as appropriate.
For non-commercial use only
Shire CONFIDENTIAL Page 57
SHP643 -102 Protocol
Lanadelum ab 29 Jan 2019
APPENDIX 3.2 SPONSOR’S RESPONSIBI LITIES
Good Clinical Practice Compliance
The study  sponsor and any  third party  to whom aspects of the study  management or monitoring 
have been delegated will undertake their assigned roles for this study  in co mpliance with all 
applicable industry  regulations, current ICH GCP guideline E6 (1996), EU Directive 2001/20/EC 
Guidelines, as well as all applicable national and local laws and regulations.
Visits to sites are conducted by  [CONTACT_10199]/or the company  
organizing/managing the research on behalf of the sponsor to inspect study  data, subjects’ 
medical records, and CRFs in accordance with current GCP and the respective local and 
(inter)national government regulations and guidelines. Records and data may  additionally  be 
reviewed b y auditors or by  [CONTACT_10200].
The sponsor ensures that local regulatory  authority requirements are met before the start of the 
study .  The sponsor (or a nominated designee) is responsible for the p reparation, submission, and 
confirmation of receipt of an y regulatory  authority  approvals required prior to release of 
investigational product for shipment to the site.
Indemnity/Liability and Insurance
The sponsor will ensure that suitable clinical study insurance coverage is in place prior to the 
start of the study .  An insurance certificate will be supplied to the investigator as necessary .
Public Posting of Study Information
The sponsor is responsible for posting appropriate study information on applica ble websites.  
Information included in clinical study  registries may  include participating investigators’ names 
and contact [CONTACT_3031].
The timing for stud y registration and results summary posting(s) must be in accordance with 
applicable local and national requirements.
Submission of Summary of Clinical Study Report to Competent Authorities of Member 
States Concerned and Ethics Committees
The sponsor will provide a summary  of the clinical study  report to the competent authority  of the 
member state(s ) concerned as required by  [CONTACT_64724](s) and to comply  with the 
Community  guideline on GCP.  This requirement will be fulfilled within 6 months of study  
completion date for pediatric studies and within 1 y ear for non- pediatric studies as per guidance.   
Study Suspension, Termination, and Completion
The sponsor may  suspend or terminate the study , or part of the study , at any  time for any  reason.  
If the stud y is suspended or terminated, the sponsor will ensure that applicable sites, regulatory 
agencies and IRBs/ECs are notified as appropriate.  Additionally, the discontinuation of a 
For non-commercial use only
Shire CONFIDENTIAL Page 58
SHP643 -102 Protocol
Lanadelum ab 29 Jan 2019
registered clinical study  which has been posted to a designated public website will be updated 
accordingl y.
For non-commercial use only
Shire CONFIDENTIAL Page 59
SHP643 -102 Protocol
Lanadelum ab 29 Jan 2019
APPENDIX 3.3 INVESTIGATOR’S RESPO NSIBILITIES
Good Clinical Practice Comp liance
The investigator must undertake to perform the study  in accordance with ICH GCP Guideline E6 
(1996) and E6 R2 (2017), EU Directive 2001/20/EC, and applicable regulatory  requirements and 
guidelines.
It is the investigator’s responsibility  to ensure t hat adequate time and appropriately  trained 
resources are available at the site prior to commitment to participate in this study .  The 
investigator should also be able to estimate or demonstrate a potential for recruiting the required 
number of suitable su bjects within the agreed recruitment period.
The investigator will maintain a list of appropriately  qualified persons to whom the investigator 
has delegated significant study -related tasks, and shall, upon request of the sponsor, provide 
documented evidenc e of any  licenses and certifications necessary  to demonstrate such 
qualification.  Curriculum vitae for investigators and sub- investigators are provided to the study  
sponsor (or designee) before starting the study .
If a potential research subject has a pri mary  care phy sician, the investigator should, with the 
subject’s consent, inform them of the subject’s participation in the study .
Agreement with the final clinical study  report will be documented b y the signed and dated 
signature [CONTACT_709216], in compliance with Directive 2001/83/EC as amended b y 
Directive 2003/63/EC and I CH Guidance E3 ( 1995). 
Protocol Adherence and Investigator Agreement
The investigator and an y sub
-investigators must adhere to the protocol as detailed in this 
document.  The investigator is responsible for enrolling only  those subjects who have met 
protocol eligibility  criteria.  Investigators are required to sign an investigator agreement to 
confirm acceptance and willingness to comply  with the study  protocol.
If the investigator suspends or terminates the study  at their site, the investigator will promptly  
inform the sponsor and the I RB/EC and provide them with a detailed written explanation.  The 
investigator will also return all investigational product, containers, an d other study  materials to 
the sponsor.  Upon study  completion, the investigator will provide the sponsor, I RB/EC, and 
regulatory  agency  with final reports and summaries as required by  (inter)national regulations.
Communication with local I RBs/ECs, to ensure accurate and timel y information is provided at 
all phases during the study , may  be done by  [CONTACT_456], applicable CRO, investigator, or for 
multicenter studies, the coordinating principal investigator [INVESTIGATOR_709203].
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_964275] separate source documentation; no da ta will be recorded directly  onto the 
CRF.
All data sent to the sponsor must be endorsed b y the investigator.
The CRA/study  monitor will verify  the CRF contents against the source data per the monitoring 
plan. If the data are unclear or contradictory , quer ies will be issued for corrections or verification 
of data.
Recording, Access, and Retention of Source Data and Study Documents
Original source data to be reviewed during this study  will include, but are not limited to: 
subject’s medical file , and original clinical laboratory  reports.
All key  data must be recorded in the subject’s source documents.
The investigator must permit authorized representatives of the sponsor, the respective national, 
local, or foreign regulatory  authorities, the IRB/EC, and auditors to inspect facilities and to have 
direct access to original source records relevant to this study , regardless of media.
The CRA/study  monitor (and auditors, IRB/EC or regulatory  inspectors) may  check the CRF 
entries against the source documents.  The co nsent form includes a statement by  [CONTACT_10203]/auditor from the sponsor or its representatives, national or local 
regulatory  authorities, or the I RB/EC, having access to source data (eg, subject’s medical file, 
appointment books , original laboratory  reports, X -rays etc.).   
These records must be made available within reasonable times for inspection and duplication, if 
required, b y a properly  authorized representative of any  regulatory  agency  (eg, the US FDA, 
EMA, [LOCATION_006] Medicines and Healthcare products Regulatory  Agency ) or an auditor.
Essential documents must be maintained according to ICH GCP requirements and may  not be 
destroy ed without written permission from the sponsor.
Audit/Inspection
To ensure compliance with relevant regulations, data generated b y this study must be available 
for inspection upon request by  [CONTACT_1779], for example, the US FDA (as well as other US 
national and local regulatory  authorities), the EMA, the Medicines and Healthcare products 
For non-commercial use only
Shire CONFIDENTIAL Page 61
SHP643 -102 Protocol
Lanadelum ab 29 Jan 2019
Regulator y Agency , other regulatory  authorities, the sponsor or its representatives, and the 
IRB/EC for each site.
Financial Disclosure
The investigator is required to disclose an y financial arrangement during the study and for 1 year 
after, whereb y the outcome of the study  could be influenced by  [CONTACT_10204] , or other pay ments the investigator received from the sponsor.  The 
following information is collected: an y significant payments from the sponsor or subsidiaries 
such a s a grant to fund ongoing research, compensation in the form of equipment, retainer for 
ongoing consultation or honoraria; an y proprietary interest in investigational product; an y 
significant equity  interest in the sponsor or subsidiaries as defined in 21 CFR 54 2(b) (1998).
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_964276]’s legall y-authorized representative, as applicable, is requested to sign and date the subject 
informed consent form or a certified translation if applicable, afte r the subject has received and 
read (or been read) the written subject information and received an explanation of what the study 
involves, including but not limited to: the objectives, potential benefits and risk, inconveniences, 
and the subject’s rights a nd responsibilities.  A copy  of the informed consent documentation (ie, 
a complete set of subject information sheets and fully  executed signature [CONTACT_1787]) must be given to 
the subject or the subject’s legally  authorized representative, as applicable.  This d ocument may  
require translation into the local language.  Signed consent forms must remain in each subject’s 
study  file and must be available for verification at any  time.
The principal investigator [INVESTIGATOR_1682] a cop y of the consent form whic h was 
reviewed b y the IRB/EC and which received their favorable opi[INVESTIGATOR_1649]/approval.  A cop y of the 
IRB/EC’s written favorable opi[INVESTIGATOR_1649]/approval of these documents must be provided to the 
sponsor, prior to the start of the study  unless it is agreed to and docu mented (abiding b y 
regulatory  guidelines and national provisions) prior to study  start that another part y (ie, sponsor 
or coordinating principal investigator) is responsible for this action.  Additionally, if the IRB/EC 
requires modification of the sample subject information and consent document provided by  [CONTACT_103], the documentation supporting this requirement must be provided to the sponsor.
Institutional Review Board or Ethics Committee
For sites outside the EU, it is the responsibility  of the invest igator to submit this protocol, the 
informed consent document (approved b y the sponsor or their designee), relevant supporting 
information and all ty pes of subject recruitment information to the I RB/EC for review, and all 
must be approved prior to site ini tiation.
The applicant for an EC opi[INVESTIGATOR_317340]; 
for multicenter studies the applicant can be the coordinating principal investigator [INVESTIGATOR_10157], 
according to national provisions.
Responsibility  for coordinating with IRBs/ECs is defined in the clinical trial agreement.
Investigational product supplied will not be released until the sponsor and/or CRO have received 
written I RB/EC approval.
Prior to implementing changes in the study , the sponsor and the IRB/EC must approve an y 
revisions of all informed consent documents and amendments to the protocol unless there is a 
subject safet y issue. If required by [CONTACT_1769], substantial amendments to the protocol must also 
be approved b y the appropriate regulatory agency  prior to implementation.
For non-commercial use only
Shire CONFIDENTIAL Page 63
SHP643 -102 Protocol
Lanadelum ab 29 Jan 2019
For sites outside the EU, the investigator is responsible for keepi[INVESTIGATOR_1683]/EC appraised of the 
progress of the stud y and of an y changes made to the protocol, at least annually  or more 
frequentl y in accordance with the re quirements, policies, and procedures established by  [CONTACT_5040]/EC. This can be the responsibility  of the sponsor or investigator for sites within the EU; or 
for multicenter studies, the coordinating principal investigator, according to national provisions.  
The investigator must also keep the local I RB/EC informed of any  serious and significant AEs as 
required b y IRB/EC procedures.
Privacy and Confidentiality
All US-based sites and laboratories or entities providing support for this study , must, where 
applicable, compl y with the HIPAA of 1996.  A site that is not a covered entity  as defined by  
[CONTACT_709212]/or CRO.
The confidentialit y of records that may be able to identify subjects will be protected in 
accorda nce with applicable laws, regulations, and guidelines.
After subjects have consented to take part in the study , the sponsor and/or its representatives’ 
reviews their medical records and data collected during the stud y.  These records and data may, 
in addit ion, be reviewed by [CONTACT_1774]: independent auditors who validate the 
data on behalf of the sponsor; third parties with whom the sponsor may  develop, register, or 
market lanadelumab ; national or local regulatory  authorities; and the I RB(s)/EC(s) which gave 
approval for the study  to proceed.  The sponsor and/or its representatives accessing the records 
and data will take all reasonable precautions in accordance with applicable laws, regulations, and 
guidelines to maintain the confidentia lity of subjects’ identities.
Subjects are assigned a unique identify ing number; however, their initials and date of birth may  
also be collected, if permitted under local laws governing privacy .
The results of studies containing subjects’ unique identify ing number, relevant medical records, 
and possibly  initials and dates of birth, where allowed per local law, may  be transferred to, and 
used in, other countries which may  not afford the same level of protection that applies within the 
countries where this st udy is conducted.  The purpose of an y such transfer would include: to 
support regulatory  submissions, to conduct new data anal yses to publish or present the study  
results, or to answer questions asked by  [CONTACT_1775].
Study Results / Pu blication Policy
The term “Publication” shall mean an y paper, article, manuscript, report, poster, internet posting, 
presentation slides, abstract, outline, video, instructional material, presentation (in the form of a 
written summary ), or other public disclosure of the study  results, in printed, electronic, oral, or 
other form. The parties understand and agree that participation in the study  may  involve a 
commitment to publish the data from all sites participating in the study  in a cooperative 
publication with other investigators prior to publication or oral presentations of the study  results 
on an individual basis. The site agrees not to publish or present the site’s study  results until such 
time as either the aggregate multi
-site study  results are published in a cooperative publication or 
for a period of one (1) year after termination or completion of the study  at all participating sites, 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_964277] occur. After that time, the site may  publish the site’s study  results in 
scientific journals or p resent the study  results at symposia or other professional meetings in 
accordance with the following provisions:
If the stud y is part of a multicenter study, the first publication of the study results shall be made 
by [CONTACT_709213]’s presentation of a joint, multicenter publication 
of the compi[INVESTIGATOR_10163].  If such a multicenter publication is not submitted to 
a journal for publication by [CONTACT_10209] [ADDRESS_964278] sixty  (60) day s prior to submitting an abstract, manuscript, or other document for 
publication, a cop y of the proposed publicat ion will be provided to the sponsor by  [CONTACT_49134].  Upon the sponsor’s request, the site agrees to remove an y and all confidential 
information (expressly  excluding study  results) identified in the publication and to delay  such 
submission or presen tation for an additional sixty  (60) day  period in order to allow the sponsor 
time to file any  patent application(s).  All publications of the study  results shall appropriatel y 
reference the multi- site study  publication, if an y, or the fact that the study r esults are a subset of 
data resulting from a larger multi- site study .
Shire is committed to transparent dissemination of all scientific, technical and medical 
manuscripts generated from Shire -supported research. Therefore, after January  1, 2018, Shire 
willrequire the submission of all Shire -supported research manuscripts to journals that offer 
public availability  via Open Access (including publisher platforms/repositories and self -
archiving). Open Access refers to the free at point of entry , online availab ility of published 
research output with, where available, rights of re- use according to an End User License.
Unless otherwise required by  [CONTACT_10210], or the forum in which 
it is made, authorship will comply  with the Intern ational Committee of Medical Journal Editors 
(ICMJE) Recommendation for the Conduct, Reporting, Editing and Publication of Scholarl y 
Work in Medical journals. Participation as an investigator does not confer any rights to 
authorship of publications.
For non-commercial use only
Shire CONFIDENTIAL Page 65
SHP643 -102 Protocol
Lanadelum ab 29 Jan 2019
APPENDIX 4 ADVER SE EVENTS: DEFINITIO NS AND PROCEDURES FO R 
RECORDING, EVALUATING, FOLLOW -UP, AND REPORTING
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_964279]. An AE can therefore be an y unfavorable and 
unintended sign (including an abnormal laboratory finding), s ymptom, or disease temporally  
associated with the use of a medicinal (investigational) product, whether or not related to the 
medicinal (investigational) product (ICH Guidance E2A 1995).
Treatment -emergent Adverse Event
A treatment -
emergent adverse event (TEAE) is defined as an y event emerging or manifesting at 
or after the initiation of treatment with an investigational product or medicinal product or an y 
existing event that worsen s in either intensity  or frequency  following exposure to the 
investigational product or medicinal product. 
Serious Adverse Event 
A serious adverse e vent (SAE) is any  untoward medical occurrence (whether considered to be 
related to investigational product or not) that at any  dose:
Results in death
Is life -threatening.  Note: The term ‘life- threatening’ in the definition of “serious” refers 
to an event in which the subject was at risk of death at the time of the event; it does not 
refer to an event which hy pothetically  might have caused death if it was more severe.
Requires inpatient hospi[INVESTIGATOR_1081].  Note: 
Hospi[INVESTIGATOR_602], that are the result of elective or previously  scheduled investigations 
procedures or surger y for pre -existing conditions and have not worsened after initiation 
of treatment, should not be classified as SAEs. For example, an admission for a 
previously  scheduled ventral hernia repair would not be classified as an SAE; however, 
complication(s) resu lting from a hospi[INVESTIGATOR_543507](s) serious criteria must be reported as SAE(s).
Results in persistent or significant disability /incapacity
Results in a congenital abnormality /birth defect
Is an important medical event.  Note: I mportant medical events that may not result in 
death, be life -threatening, or require hospi[INVESTIGATOR_12475], 
based upon appropriate medical judgment, they  may  jeopardize the subject and may  
require m edical or surgical intervention to prevent 1 of the outcomes listed in this 
definition.  Examples of such medical events include bronchospasm associated with 
anaph ylaxis requiring intensive treatment in an emergency  room or at home; blood 
dyscrasias or convulsions that do not result in inpatient hospi[INVESTIGATOR_059]; or the 
development of drug dependency  or drug abuse.
For non-commercial use only
Shire CONFIDENTIAL Page 67
SHP643 -102 Protocol
Lanadelum ab 29 Jan 2019
Unexpected Adverse Event
An unexpected adverse event is an AE whose nature, severity, specificit y, or outcome is not 
consistent with the term, re presentation, or description used in the Reference Safet y Information 
(RSI ). “Unexpected” also refers to the AEs that are mentioned in the IB and/or prescribing 
information as occurring with a class of drugs or as anticipated from the pharmacological 
prope rties of the product, but are not specificall y mentioned as occurring with the particular 
product under investigation. 
The expectedness of AEs will be determined b y the sponsor using the IB and/or prescribing 
information as the RSI . This determination wil l include considerations such as the number of 
AEs previously  observed, but not on the basis of what might be anticipated form the 
pharmacological properties of a product.
Suspected Unexpected Serious Adverse Reaction 
A Suspected Unexpected Serious Advers e Reaction (S[LOCATION_003]R) is defined as any  suspected 
adverse reaction to study  treatment (ie, including active comparators) that is both serious and 
unexpected. 
The event(s) must meet all of the following:
Suspected adverse reaction
Serious
Unexpected
Assessed as related to study  treatment
Unanticipated Adverse Device Effect 
An unanticipated adverse device effect (UADE) is any  serious adverse effect on health or safet y 
or an y life -threatening problem or death caused by, or associated with, a device, if that eff ect, 
problem, or death was not previously  identified in nature, severity , or degree of incidence in the 
study  protocol or product labeling; or any  other unanticipated serious problem associated with a 
device that relates to the rights, safet y, or welfare of subjects.
Clinical Laboratory and Other Safety Assessment
A change in the value of a clinical laboratory  parameter, vital sign measure, or ECG assessment 
can represent an AE if the change is clinically  relevant or if, during administration of 
investigati onal product, a shift of a parameter is observed from a value in the normative range to 
a value that is outside the normal range and considered clinically  significant, or a further waning 
of an alread y clinicall y significant value. When evaluating such cha nges, the extent of deviation 
from the reference range, the duration until return to the reference range, either while continuing 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_964280], and the range
of variation of the respecti ve parameter within its reference range, should also be considered.
If, at the end of the treatment phase, there are abnormal clinical laboratory  (such as hematology  
panel or clinical chemistry  panel), vital sign, or ECG values which were not present at th e 
pretreatment evaluation observed closest to the start of study  treatment, further investigations 
should be performed until the values return to within the reference range or until a plausible 
explanation (eg, concomitant disease or expected disease evolu tion) is found for the abnormal 
values.
The investigator should assess, based on the above criteria and the clinical condition of the 
subject, whether a change in a clinical laboratory  value, vital sign, or ECG parameter is clinicall y 
significant and repre sents an AE.
For non-commercial use only
Shire CONFIDENTIAL Page 69
SHP643 -102 Protocol
Lanadelum ab 29 Jan 2019
APPENDIX 4.2 COLLECTION OF ADVERS E EVENTS
All AEs/SAEs are collected from the time the informed consent is signed until the defined 
follow -up period stated in Section [IP_ADDRESS]. This includes events occurring during the screening 
phase of the stud y, regardle ss of whether or not investigational product is administered. 
All AEs/SAEs must be followed to closure (the subject’s health has returned to his/her baseline 
status or all variables have returned to baseline), regardless of whether the subject is still 
participating in the stud y. Closure indicates that an outcome is reached, stabilization achieved 
(the investigator does not expect any  further improvement or worsening of the event), or the 
event is otherwise explained.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_964281] dose of a 
new AE of severe d yspepsia (with the appropriate date of onset) should be documented in the 
source.
The medical assessment of severit y is determined by [INVESTIGATOR_1477]:
Mild: A type of AE that is usually  transient and may  require only  minimal treatment or 
therapeutic intervention.  The event does not generally  interfere with usual 
activities of daily  living.
Moderate: A type of AE that is usually  alleviated with specific therapeutic intervention.  The 
event interferes with usual activities of daily  living, causing discomfort but poses 
no significant or permanent risk of harm to the research subject.
Severe: A type of AE that interrupts usual activities of daily  living , or significantl y 
affects clinical status, or may  require intensive therapeutic intervention.
Relationship Categorization
A phy sician/investigator must make the assessment of relationship to investigational product for 
each AE. The investigator should decide whether, in his or her medical judgment, there is a 
reasonable possibility  that the event may  have been caused b y the investigational product. If 
there is no valid reason for suggesting a relationship, then the AE should be classified as “not 
related”. Otherwise, if there is an y valid reason, even if undetermined or untested, for suspecting 
a possible cause -and-effect relationship between the investigational product and the occurrence 
of the AE, then the AE should be considered “related”. The causal ity assessment must be 
documented in the source.
For non-commercial use only
Shire CONFIDENTIAL Page 71
SHP643 -102 Protocol
Lanadelum ab 29 Jan 2019
The following additional guidance may  be helpful:
Term Relationship Definition
RelatedThe temporal relationship between the event and the administration of the 
investigational product is compelling and/or follows a known or suspected 
response pattern to that product, and the event cannot be explained by [CONTACT_423]’s 
medical condition, other therapi[INVESTIGATOR_014], or accident.
Not RelatedThe event can be readily explained by [CONTACT_1605]’s underlying 
medical condition, concomitant therapy, or accident and no plausible temporal or 
biologic relationship exists between the investigational product and the event.
Outcome Categorization
The outcome of AEs must be recorded in the source during the course of the study . Outcomes are 
as follows:
Fatal
Not Recovered/Not Resolved
Recovered/Resolved
Recovered/Resolved With Sequelae
Recovering/Resolving
Unknown
If applicable, action taken will also be recorded on the AE CRF. 
For non-commercial use only
Shire CONFIDENTIAL Page 72
SHP643 -102 Protocol
Lanadelum ab 29 Jan 2019
APPENDIX 4.4 SAFETY REPORTING
Reference Safety Information
The reference for safet y information for this study  is the lanadelumab investigator’s brochure 
version 6.[ADDRESS_964282] be reported by  [CONTACT_709214] y Department and the CRO/Shire Medical Monitor within 24 hours of becoming 
aware of the event.  Note:  The 24 -hour reporting requirement for SAEs does not apply  to reports 
of abuse, misuse, overdose, or medication errors (see Appendix 4.9) unless they  result in an 
SAE.
The investigator must complete, sign, and date the Shire “Clinical Study  Serious Adverse Event 
for Serious Adverse Events (SAEs) and Non- seriou s AEs as Required b y Protocol ” Form and 
verify  the accuracy  of the information recorded on the form with the corresponding source 
documents (Note:  Source documents are not to be sent unless requested), and fax or e -mail the 
form to the Shire Global Drug Safet y Department.  A cop y of the Shire Clinical Study  Serious 
Adverse Event Form for Serious Adverse Events (SAEs) and Non- serious AEs as Required b y 
Protocol (and an y applicable follow -up reports) must also be sent to the CRO/Shire Medical 
Monitor using the details specified in the e mergency  contact [CONTACT_1739].
For non-commercial use only
Shire CONFIDENTIAL Page 73
SHP643 -102 Protocol
Lanadelum ab 29 Jan 2019
APPENDIX 4.5 SERIOUS ADVERSE EVEN T COLLECTION TIME FR AME
All SAEs (regardless of relationship to investigational product) are collected from the time the 
subject signs the informed consent until the defined follow -up period stated in Section [IP_ADDRESS], 
and must be reported to the Shire Global Drug Safety  Department and the CRO/Shire Medical 
Monitor within [ADDRESS_964283] awareness of the event.
In addition, any  SAE(s) considered “related” to the investigational p roduct and discovered by  [CONTACT_10194] y interval after the study has completed must be reported to the Shire Global 
Drug Safet y Department within [ADDRESS_964284]’s death (eg, the SAE was noted as the primary  cause of 
death) must have fatal checked as an outcome with the date of death recorded as the resolution 
date.  For all other events ongoing at the time of death that did not contribute to the subject’s 
death, the outcome should be considered not resolved, without a resolution date recorded.
For an y SAE that results in the subject’ s death or any  ongoing events at the time of death, unless 
another investigational product action was previously  taken (eg, drug interrupted, reduced, 
withdrawn), the action taken with the investigational product should be recorded as “dose not 
changed” or “not applicable” (if the subject never received investigational product or it is a 
single dose stud y). The investigational product action of withdrawn should not be selected solel y 
as a result of the subject’s death.
For non-commercial use only
Shire CONFIDENTIAL Page 76
SHP643 -102 Protocol
Lanadelum ab 29 Jan 2019
APPENDIX 4.8 PREGNANCY
All pregnancies are to be reported from the time informed consent is signed until the defined 
follow -up period stated in Section [IP_ADDRESS].
Any report of pregnancy  for any  female study  or the partner of a male study  participant must be 
reported within 24 hours to the Shire Global Drug Safety  Department using the Shire 
Investigational and Marketed Products Pregnancy  Report Form. A copy  of the Shire 
Investigational and Marketed Products Pregnancy  Report Form (and any  applicable follow -
up 
reports) must also be sent to the CRO/Shire Medical Monitor using the details specified in the 
emergency  contact [CONTACT_1739]. The pregnant female study  participant 
must be withdrawn from the study .
Every  effort should be made to gather information regarding the pregnancy  outcome and
condition of the infant. It is the responsibility  of the investigator to obtain this information within 
[ADDRESS_964285]-partum.
Pregnancy  complications such as spontaneous abortion/miscarriage, elective abortion or 
congenital abnormalit y are considered SAEs and must be reported using the Shire Clinical Study  
Serious Adverse Event and Non- serious AEs Required by  [CONTACT_10191].  
In addition to the above, if the investigator determines that the pregnancy  meets serious criteria, 
it must be reported as an SAE using the Shire Clinical Study  Serious Adverse Event and Non-
serious AEs Required b y the Protocol Form as well as the Shire Investigational and Marketed 
Products Pregnancy  Report Form. The test date of the first positive serum/urine -HCG test or 
ultrasound result will determine the pregnancy  onset date.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_964286] OSE, AND MEDICATION ERROR
Abuse, misuse, overdose, or medication error (as defined below) must be reported to the sponsor 
according to the SAE reporting procedure whether or not they  result in an AE/SAE as described 
in Append ix 4.1. 
Note: The 24
-hour reporting requirement for SAEs does not apply to reports of abuse, misuse, 
overdose, or medication error s unless these result in an SAE. 
The categories below are not mutually  exclusive; the event can meet more than 1 category .
Abuse –Persistent or sporadic intentional intake of investigational product when used for 
a non -medical purpose (eg, to alter one’s state of consciousness or get high) in a manner 
that may  be detrimental to the individual and/or society
Misuse –Intentional use of investigational product other than as directed or indicated at 
any dose (Note: this includes a situation where the investigational product is not used as 
directed at the dose prescribed by  [CONTACT_760])
Overdose –
Intentional or unintentional intake of a dose of investigational product higher 
than the protocol -prescribed dose
Medication Error –An error made in prescribing, dispensing, administration, and/or use 
of an investigational product.  For studies, medication errors are reportable to the sponsor 
only as defined below
Cases of subjects missing doses of the investigational product are no t considered reportable as 
medication errors.
Medication errors should be collected/reported for all products under investigation.
The administration and/or use of the unassigned treatment is/are alway s reportable as a 
medication error.
The administration and/or use of an expi[INVESTIGATOR_10151] a 
reportable medication error.
The administration of investigational product to an eligible volunteer following a temperature 
excursion as outlined in the pharmacy  manual, without ass essment of the excursion and 
permission of the sponsor to proceed is deemed a medication error and a protocol deviation.
It is not expected that overdose would occur in this study . The investigational product used in 
this study  is supplied in 1strength (30 0 mg) and is administered once per volunteer by  a trained 
and responsible staff member at the stud y site with sponsor oversight. 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_964287] subjects participating in a clinical trial from immediate harm, these do not 
constitute de facto deviation from the protocol. Urgent safet y measures may be taken b y the 
sponsor or clinical investigator, and may  include any  of the following:
Immediate change in study  design or stud y procedures
Temporary  or permanent halt of a given clinical trial or trials
Any other immediate action taken in order to protect clinical trial participants from 
immediate hazard to their health and safet y
The investig ator may  implement urgent safety  measures to protect study  subjects from 
immediate hazard to their health or safet y. The measures should implement immediately  and 
does not require prior authorization from the sponsor. In the event(s) of an apparent direct hazard 
to the subject, the investigator will notify  the sponsor immediately  by [CONTACT_49137], and  within 1 calendar day after the 
change is implemented. The sponsor will also ensure the respon sible EC(s) and relevant 
competent authorit y(s) are notified of the urgent safet y measures taken in such cases according to 
local regulations. 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_964288], 
ETHICS COMMITTEE, AN D SITE REPORTING
Thesponsor and clinical CRO areresponsible for notify ing the relevant regulatory  
authorities/ US local I RB of related, unexpected SAEs.
In addition the sponsor is responsible for notify ing active sites of all related, unexpected SAEs 
occurring during all interventional studies ac ross the SHP643 
program.   
The investigator is responsible for notify ing the local IRB/EC of SAEs or significant safet y 
findings, or the relevant local regulatory  authorit y of all SAEs that occur at his or her site as 
required b y IRB/EC procedures.
For non-commercial use only